amikacin has been researched along with meropenem in 242 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (0.41) | 18.7374 |
1990's | 18 (7.44) | 18.2507 |
2000's | 90 (37.19) | 29.6817 |
2010's | 90 (37.19) | 24.3611 |
2020's | 43 (17.77) | 2.80 |
Authors | Studies |
---|---|
Chen, YG; Du, XX; Li, LJ; Shen, P; Wei, ZQ; Yu, YS | 1 |
Alba, L; Chen, Y; Garber, E; Saiman, L; Tabibi, S; Zhou, J | 1 |
Furuno, JP; Graffunder, E; Graves, J; Lodise, TP; Lomaestro, B; McGregor, JC; McNutt, LA; Miller, CD | 1 |
Adams, J; de Oliveira Garcia, D; Doi, Y; Paterson, DL | 1 |
Bouza, E; Cercenado, E; Cuevas, O; Marín, M; Martínez-Alarcón, J; Sánchez-Martínez, M | 1 |
Barth, AL; Castanheira, M; Gales, AC; Nicoletti, AG; Pereira, AS; Pignatari, AC | 1 |
Dumas, JL; Köhler, T; Reinhardt, A; Ricou, B; Rohner, P; van Delden, C; Wood, P | 1 |
Correa, A; Kattan, JN; Lolans, K; Lopez, JA; Quinn, JP; Villegas, MV | 1 |
Noskin, GA; Obias, A; Postelnick, MJ; Qi, C; Scheetz, MH; Warren, JR; Zembower, T | 1 |
Caniça, M; Ferreira, E; Leitão, J; Manageiro, V; Mendonça, N | 1 |
Cauda, R; Citton, R; D'Inzeo, T; Fadda, G; Fiori, B; Montuori, E; Posteraro, B; Sanguinetti, M; Spanu, T; Trecarichi, EM; Tumbarello, M | 1 |
Bonomo, RA; Endimiani, A; Hujer, AM; Hujer, KM; Luzzaro, F; Mantengoli, E; Migliavacca, R; Pagani, L; Rossolini, GM; Toniolo, A | 1 |
Ariza, J; Dominguez, MA; Gudiol, F; Guzmán, A; Peña, C; Pujol, M; Suarez, C; Tubau, F | 1 |
Kamat, V; Sekar, U; Toleman, MA; Vinodh, H; Walsh, TR | 1 |
Avlami, A; Daikos, GL; Katsilambros, N; Kosmidis, C; Petrikkos, G; Psychogiou, M; Stefanou, I; Tassios, PT; Vasilakopoulou, A | 1 |
Castanheira, M; Jones, RN; Mendes, RE; Sader, HS; Toleman, MA; Walsh, TR | 1 |
Afkou, Z; Ikonomidis, A; Labrou, M; Maniatis, AN; Pournaras, S; Sofianou, D; Tsakris, A | 1 |
Carmeli, Y; Chmelnitsky, I; Leavitt, A; Navon-Venezia, S; Schwaber, MJ | 1 |
Hovde, LB; Kroeger, LA; Mitropoulos, IF; Rotschafer, JC; Schafer, J | 1 |
Beceiro, A; Bou, G; Canle, D; Fernández, A; Lasa, I; Latasa, C; Mallo, S; Molina, F; Pérez, A; Pérez, S; Poza, M; Tomás, Mdel M; Villanueva, R | 1 |
Fung, CP; Hsieh, YP; Hu, WS; Lin, JF; Liu, CP; Yao, SM | 1 |
Chen, M; Guo, P; Sun, H; Wang, H; Xu, Y; Yang, Q; Zhu, Y | 1 |
Bouza, E; Cercenado, E; Coll, P; Gutiérrez, O; Juan, C; Navarro, F; Oliver, A; Pérez, JL | 1 |
Castanheira, M; Deshpande, LM; Fritsche, TR; Jones, RN; Sader, HS | 1 |
Baudry, PJ; DeCorby, M; Hoban, DJ; Johnson, J; Karlowsky, JA; Lagacé-Wiens, P; Laing, N; McCracken, M; Mulvey, MR; Nichol, KA; Tailor, F; Vashisht, R; Walkty, A; Weshnoweski, B; Wierzbowski, A; Zhanel, GG | 1 |
Bethel, CR; Bonomo, RA; Carias, LL; Endimiani, A; Fox, WR; Hall, GS; Hujer, AM; Hujer, KM; Hutton, RA; Jacobs, MR; Jenkins, SG; Paterson, DL; Perez, F; Rice, LB; Tenover, FC | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Carrillo, B; Esparza-Ahumada, S; Garza-Ramos, U; Hernández, E; Jones, RN; Morfin-Otero, R; Rodriguez-Noriega, E; Sader, HS; Sanchez, A; Silva-Sanchez, J | 1 |
Apisarnthanarak, A; Kiratisin, P; Laesripa, C; Saifon, P | 1 |
Alba, V; Blasco, MD; Espinal, P; Fernández-Cuenca, F; Marti, S; Pascual, A; Ruiz, M; Sánchez-Céspedes, J; Vila, J | 1 |
Badur, S; Cagatay, AA; Carrër, A; Eraksoy, H; Nordmann, P; Poirel, L | 1 |
Carmeli, Y; Chmelnitsky, I; Navon-Venezia, S; Strahilevitz, J | 1 |
Fukuoka, T; Kakuta, M; Koga, T; Masuda, N; Namba, E; Sugihara, C | 1 |
Cauda, R; D'Inzeo, T; De Pascale, G; Fadda, G; Fiori, B; Leone, F; Rossi, M; Sali, M; Sanguinetti, M; Spanu, T; Trecarichi, EM; Tumbarello, M | 1 |
Bratu, S; Georgescu, C; Landman, D; Martin, DA; Quale, J | 1 |
Amsler, KM; Bush, K; Davies, TA; Jacobs, MR; Shang, W | 1 |
Albertí, S; Beceiro, A; Bou, G; Garau, M; Gutiérrez, O; Juan, C; Oliver, A; Pérez, JL | 1 |
Afif, C; Bagattini, M; Daoud, Z; Di Popolo, A; Khan, AU; Triassi, M; Vitale, D; Zarrilli, R | 1 |
Adams-Haduch, JM; Doi, Y; Harrison, LH; Muto, CA; Pasculle, AW; Paterson, DL; Potoski, BA; Sidjabat, HE | 1 |
Bauraing, C; Bogaerts, P; Cuzon, G; Deplano, A; Glupczynski, Y; Lissoir, B; Naas, T; Nordmann, P | 1 |
Chen, H; Chen, M; Wang, H; Yang, H; Yang, Q | 1 |
Amicosante, G; De Luca, F; Luzzaro, F; Migliavacca, R; Mugnaioli, C; Pagani, L; Perilli, M; Pini, B; Pollini, S; Rossolini, GM; Spalla, M; Toniolo, A | 1 |
Bennett, JW; Herrera, ML; Jorgensen, JH; Lewis, JS; Wickes, BW | 1 |
Baptista, BC; Correia, JD; da Fonseca, JD; Martínez-Martínez, L; Pomba, C | 1 |
Bell, JM; Castanheira, M; Deshpande, LM; Jones, RN; Mendes, RE; Turnidge, JD | 1 |
Bell, JM; Castanheira, M; Jones, RN; Mathai, D; Turnidge, JD | 1 |
Baraniak, A; Bedenic, B; Fiett, J; Gniadkowski, M; Jajic-Bencic, I; Literacka, E; Tonkic, M | 1 |
Duljasz, W; Gniadkowski, M; Jebelean, C; Sitter, S; Wojna, A | 1 |
Della-Latta, P; Dib-Hajj, F; Dougherty, BA; Gootz, TD; He, W; Huard, RC; Lescoe, MK | 1 |
Jones, RN; Leonard, SN; Rybak, MJ; Sader, HS; Vidaillac, C | 1 |
Kirikae, T; Kitao, T; Miyoshi-Akiyama, T | 1 |
Capone, A; D'Andrea, MM; D'Arezzo, S; Giani, T; Luzzaro, F; Petrosillo, N; Rossolini, GM; Visca, P | 1 |
Gales, AC; Nordmann, P; Picão, RC; Poirel, L | 1 |
Baraniak, A; Fiett, J; Filczak, K; Gniadkowski, M; Herda, M; Hryniewicz, W; Izdebski, R; Kern-Zdanowicz, I; Łopaciuk, U | 1 |
Du, X; Ji, S; Jiang, Y; Li, L; Shen, P; Wei, Z; Yu, Y | 1 |
Carattoli, A; Ellington, MJ; Karisik, E; Livermore, DM; Underwood, A; Woodford, N | 1 |
Acosta, J; Chaves, F; Juan, C; Oliver, A; Otero, JR; Sanz, F; Viedma, E; Zamorano, L | 1 |
Albertí, S; Juan, C; Mulet, X; Oliver, A; Pérez, JL; Zamorano, L | 1 |
Gebreyes, WA; Rajamohan, G; Srinivasan, VB | 1 |
Chen, H; Chen, M; Sun, H; Wang, H; Xu, Y; Yang, Q | 1 |
Girlich, D; Nordmann, P; Poirel, L | 1 |
Ge, Y; Juan, C; Oliver, A; Pérez, JL; Zamorano, L | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Dunman, PM; Hood, MI; Jacobs, AC; Sayood, K; Skaar, EP | 1 |
Aquino, EE; León, CF; Otero, DM; Robledo, IE; Santana, JL; Santé, MI; Vázquez, GJ | 1 |
Beceiro, A; Bou, G; Doumith, M; Livermore, DM; Tomás, M; Turton, JF; Warner, M; Woodford, N | 1 |
Chang, SC; Chen, YC; Hsia, KC; Li, SY; Liao, MH; Lin, YC; Sheng, WH | 1 |
Flamm, R; Friedland, I; Kaniga, K; Lee, M; Redman, R; Tong, SY | 1 |
Carmeli, Y; Chmelnitsky, I; Goren, MG; Navon-Venezia, S | 1 |
Carmeli, Y; Chmelnitsky, I; Goren, MG; Leavitt, A; Navon-Venezia, S; Ofek, I | 1 |
Chang, FY; Chen, TL; Fung, CP; Huang, LY; Lu, PL; Siu, LK | 1 |
Barber, M; Eberly, LE; Feeney, LA; Miller, GH; Summers, A; Wortmann, G; Zapor, MJ | 1 |
Abele-Horn, M; Claus, H; Elias, J; Engelhardt, K; Frosch, M; Joseph, B; Oesterlein, A; Schoen, C; Turnwald, D; Valenza, G | 1 |
Jiang, Y; Shen, P; Wei, Z; Yu, D; Yu, Y; Zhou, Z | 1 |
Bai, N; Cai, Y; Li, R; Liang, B; Liu, Y; Wang, R | 1 |
Blázquez, J; Couce, A; Rodríguez-Rojas, A | 1 |
Chang, FY; Chen, TL; Fung, CP; Hsueh, PR; Ko, WC; Kuo, SC; Lee, YT; Siu, LK | 1 |
Bogaerts, P; Buvens, G; Glupczynski, Y; Lauwers, S; Piérard, D | 1 |
Chien, CC; Lee, CH; Li, CC; Liu, JW; Su, LH; Tang, YF | 1 |
Hamprecht, A; Higgins, PG; Schneiders, T; Seifert, H | 1 |
Arcari, JT; Barham, R; Brown, MF; Casavant, J; Gerstenberger, BS; Han, S; Hardink, JR; Harris, TM; Hoang, T; Huband, MD; Lall, MS; Lemmon, MM; Li, C; Lin, J; Marr, ES; McCurdy, SP; McElroy, E; McPherson, C; Mitton-Fry, MJ; Mueller, JP; Mullins, L; Nikitenko, AA; Noe, MC; Penzien, J; Plummer, MS; Schuff, BP; Shanmugasundaram, V; Starr, JT; Sun, J; Tomaras, A; Young, JA; Zaniewski, RP | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, CL; Clark, RB; Deng, Y; Fyfe, C; Grossman, TH; He, M; Hunt, DK; Sun, C; Sutcliffe, JA; Xiao, XY | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Fernando, DM; Gorityala, BK; Goswami, S; Guchhait, G; Kumar, A; Schweizer, F; Zhanel, GG | 1 |
Chen, CL; Deng, Y; Fyfe, C; Grossman, TH; Hunt, DK; Sun, C; Sutcliffe, JA; Xiao, XY | 1 |
Domalaon, R; Gorityala, BK; Goswami, S; Idowu, T; Lyu, Y; Schweizer, F; Shan, A; Yang, X; Zhanel, GG | 1 |
Bojkovic, J; Dean, CR; Dobler, M; Dzink-Fox, J; Glick, M; Hamann, LG; Kerrigan, J; Lanieri, L; Lenoir, F; Lilly, MD; Liu, E; Lu, Y; McKenney, D; Nunez, J; Osborne, C; Parker, DT; Patnaik, A; Peng, Y; Piizzi, G; Ranjitkar, S; Sprague, ER; Tommasi, R; Wang, B; Wang, H; Wattanasin, S; Xie, L; Yang, X; Yu, D | 1 |
Björkling, F; Bonke, G; Franzyk, H; Hansen, AM; Hogendorf, WFJ; Kongstad, KT; Nielsen, J; Nielsen, PE; Tomczak, M; Urbas, M; Zabicka, D | 1 |
Jiang, K; Lin, F; Wu, H; Xiao, J; Xiao, Z; Yan, X; Yu, J; Yue, Y; Zhao, M; Zhou, X | 1 |
Franzus, B; Sarubbi, F; Verghese, A | 1 |
Inderlied, CB; Lancero, MG; Young, LS | 1 |
Beuscart, C; Mouton, YJ | 1 |
Sjursen, H; Solberg, CO | 1 |
Schuler, D | 1 |
Bucaneve, G; Calandra, T; Cometta, A; Crokaert, F; de Bock, R; Del Favero, A; Gaya, H; Glauser, MP; Kern, WV; Klastersky, J; Langenaeken, I; Micozzi, A; Padmos, A; Paesmans, M; Viscoli, C; Zinner, SH | 1 |
Giamarellos-Bourboulis, EJ; Giamarellou, H; Grecka, P | 2 |
Milatovic, D; Wallrauch, C | 1 |
Elkhaïli, H; Jehl, F; Levêque, D; Linger, L; Monteil, H; Niedergang, S; Peter, JD; Pompei, D; Salmon, J; Salmon, Y; Thierry, RC | 1 |
Derevianko, II; Iakovlev, SV; Iakovlev, VP; Kira, EF | 1 |
Bonfiglio, G; Carciotto, V; Debbia, E; Nicoletti, G; Russo, G; Schito, GC; Stefani, S | 1 |
Behre, G; Hiddemann, W; Link, H; Maschmeyer, G; Meyer, P; Paaz, U; Wilhelm, M | 1 |
Babini, GS; Bates, J; Livermore, DM; Palepou, MF; Woodford, N | 1 |
Majtán, V; Majtánová, L | 1 |
Camu, F; Cornelis, PJ; De Turck, BJ; Diltoer, MW; Huyghens, LP; Maes, V; Spapen, HD | 1 |
Chanis, W; Csapó, Z; Konkoly Thege, M; Pulay, I | 1 |
Kamiya, A; Mizuno, H; Oie, S; Sawa, A | 1 |
Akan, H; Akova, M; Biberoğlu, K; Hayran, M; Kansu, E; Kars, A; Korten, V; Unal, S | 1 |
Alvarez Lerma, F | 2 |
Inoue, M; Matsuda, K | 1 |
Agaoglu, L; Agirbasli, H; Anak, S; Bilgen, H; Biner, B; Can, M; Devecioglu, O; Eryilmaz, E; Gedikoglu, G; Goksan, B; Karakas, Z; Unuvar, A; Yalman, N | 1 |
Acevedo, A; Escudero, A; Fernández-Rañada, JM; Gil-Fernández, JJ; Martínez, E; Martínez-Chamorro, C | 1 |
Anguita, A; Loscos, J; Serra, A; Vila, M; Vivancos, J | 1 |
Chinzei, T; Ishida, A; Tasaka, K | 1 |
Genkin, I; Kunin, M; Sagie, A; Salamon, F; Tur-Kaspa, R; Weinberger, M | 1 |
Bodmer, T; Fux, C; Leib, SL; Ziswiler, HR | 1 |
Chiu, HH; Hung, KC; Lin, HC; Peng, CT; Tsai, FJ; Tseng, YC; Wang, JH | 1 |
Brinkmann, G; Hellwege, HH; Kaczmarek, D; Kammler, G; Sonntag, J | 1 |
Avila-Agüero, ML; Huertas, E; Ulloa-Gutierrez, R | 1 |
Corpus, KA; Weber, KB; Zimmerman, CR | 1 |
Aksoylar, S; Cetingül, N; Kansoy, S; Kantar, M; Karapinar, D; Kavakli, K | 1 |
Abe, M; Araki, M; Horimi, T; Nasu, Y; Ono, N; Takahashi, I | 1 |
Jakoniuk, P; Leszczyńska, K; Sacha, PT; Wieczorek, P; Zalewska, M | 1 |
Bulut, Y; Demirdag, K; Kizirgil, A; Ozden, M; Toraman, ZA; Yakupogullari, Y | 1 |
Bégué, T; Bouchaud, O; Jauréguy, F; Lefort, A; Lortholary, O; Righi, S; Robineau, M | 1 |
Aydogdu, I; Ersoy, Y; Kaya, E; Kuku, I; Serefhanoglu, K; Serefhanoglu, S | 1 |
Hashikita, G; Kawakami, S; Kobayashi, S; Maesaki, S; Nagasawa, M; Okabe, T; Sasaki, K; Shibuya, S; Suzuki, N; Takayama, S; Uchida, T; Watanabe, M; Yamaguchi, T | 1 |
Doi, M; Fujiue, Y; Kuwabara, M; Muroki, K; Shimizu, S; Watanabe, Y; Yano, S | 1 |
Alp, E; Aygen, B; Metan, G; Sumerkan, B | 1 |
Bramham, K; Goldsmith, D; Schelenz, S | 1 |
Bilewska, A; Luczak, M; Młynarczyk, A; Młynarczyk, G; Pupek, J | 1 |
Dubovik, LG; Perederko, LV; Polikarpova, SV; Postnikov, SS; Semykin, SIu | 1 |
Diniz, EM; Fontes, RB; Hirooka, TM; Matushita, H; Pinto, FC | 1 |
Bannan, CL; Boutlis, CS; Chih, DT; Elston, JW | 1 |
Banerjee, S; Ganguly, S; Pant, P | 1 |
Adukauskiene, D; Dambrauskiene, A; Jeroch, J; Vitkauskiene, A | 1 |
Nakwa, F; Velaphi, S; Wadula, J | 1 |
Amicosante, G; Falcone, M; Mancini, C; Mezzatesta, ML; Perilli, M; Stefani, S; Venditti, M | 1 |
Aksoy, A; Bahat, E; Cakir, M; Dilber, B; Dilber, E; Kamaşak, T | 1 |
Brody, SL; Cannon, CL; Hogue, LA; LiPuma, JJ; Taylor, JB; Walter, MJ | 1 |
Asensi, MD; Carvalho-Assef, AP; Correal, JC; Goldemberg, DC; Leão, RS; Marques, EA; Silva, RV | 1 |
Ersoy, Y; Görgeç, S; Kuzucu, C; Yetkin, F | 1 |
Ameen, M; Arenas, R; del Mercado, EV; Vargas, F | 1 |
Hsu, LY; Kwa, AL; Lee, W; Lim, TP; Sasikala, S; Syahidah, N; Tan, TT; Tan, TY; Teo, J | 1 |
Guerra, FQ; Lima, Ede O; Melo Coutinho, HD; Mendes, JM; Morais-Braga, MF; Santos, BH; Sousa, JP | 1 |
Delattre, IK; Jacobs, F; Jacqmin, P; Laterre, PF; Musuamba, FT; Taccone, FS; Verbeeck, RK; Wallemacq, P | 1 |
Chaffanel-Peláez, M; Del Boz, J; Serrano-Martín, MM; Vera-Casaño, A | 1 |
Kimura, S; Kitazawa, T; Koga, I; Makita, E; Matsunaga, N; Okugawa, S; Ota, Y; Seo, K; Yoshino, Y | 1 |
Dowzicky, MJ; Fernández-Canigia, L | 1 |
Amudhan, MS; Balaraman, S; Kamalanathan, A; Sekar, U | 1 |
Akamatsu, T; Ikeue, H; Kitahara, T; Kitamura, M; Maeda, Y; Mori, T; Muraki, Y; Okuda, M; Shiraishi, T; Tadano, K; Takada, K; Tsugita, M; Yamada, T | 1 |
Alcántar-Curiel, MD; Alpuche-Aranda, CM; Araiza-Navarro, JR; Esparza-Ahumada, S; Flores-Vaca, M; Gayosso-Vázquez, C; González-Díaz, E; Morfín-Otero, R; Pérez-Gómez, HR; Rocha, MJ; Rodríguez-Noriega, E; Santos-Preciado, JI | 1 |
Li, Y; Liu, M; Qi, Q; Xu, L; Zhang, Y | 1 |
Alm, RA; Corbeil, J; Déraspe, M; Gardner, H; Kos, VN; McLaughlin, RE; Roy, PH; Whiteaker, JD | 1 |
Bursle, E; Cotta, MO; Gowen, B; Lipman, J; McWhinney, B; Roberts, JA; Truloff, N; Ungerer, JP | 1 |
Culebras, E; García-Salguero, C; Picazo, JJ; Rodríguez-Avial, I | 1 |
Graves, B; Hajkowicz, K; Paterson, DL; Stewart, A; Ta, K | 1 |
Crandon, JL; Hamada, Y; Nicolau, DP; So, W | 1 |
Gholipourmalekabadi, M; Hashemi, A; Mozafari, M; Rostami, A; Sameni, M; Zamani, F | 1 |
Hung, YP; Ko, WC; Lee, JC; Li, CW; Li, MC; Lin, HJ; Liu, HC; Wu, YH | 1 |
Grushnikov, A; Iino, R; Kikuchi, K; Matsumoto, Y; Nishino, K; Noji, H; Sakakihara, S; Yagi, Y; Yamaguchi, A | 1 |
Dey, AC; Dey, SK; Hossain, MI; Mannan, MA; Shahidullah, M | 1 |
Atalay, A; Demiraslan, H; Eren, E; Koc, N; Parkan, O; Ulu-Kilic, A | 1 |
de Jonge, BL; Karlowsky, JA; Kazmierczak, KM; Nichols, WW; Sahm, DF | 1 |
Banerjee, R; Boyce, TG; Cunningham, SA; Hasassri, ME; Jeraldo, PR; Kaye, KS; Norgan, AP; Patel, R; Pogue, JM; Weissman, SJ | 1 |
Cai, Y; Chan, EC; Hong, Y; Hsu, LY; Koh, TH; Kwa, AL; Lee, W; Lim, TP; Sasikala, S; Tan, TT; Tan, TY; Teo, J | 1 |
Gunasekaran, J; Shariff, M | 1 |
Boix, V; Coy, J; Garcinuño, P; Gimeno, L; Merino, E; Portilla, J; Rodríguez, JC; Sánchez-Bautista, A; Sánchez-Paya, J; Santibañez, M | 1 |
Dinic, M; Kocic, B; Mitic, R; Mladenovic-Antic, S; Petrovic, J; Randjelovic, G; Velickovic-Radovanovic, R | 1 |
Glikman, D; Hoffmann, Y; Kassem, DF; Ocampo, S; Salomon, L; Shahar, N; Zonis, Z | 1 |
Alkan, G; Emiroglu, M; Turk Dagi, H | 1 |
Chesnel, L; Howland, K; Jacqueline, C | 1 |
Doi, T; Hirota, K; Imanishi, K; Nakakura, I; Nakamori, S; Ogawa, Y; Sakakura, K; Sako, R; Shimatani, Y; Uehira, T; Yamazaki, K | 1 |
Cho, B; Chung, NG; Han, SB; Jeong, DC; Kang, JH; Kim, HS; Kim, SK; Lee, DG; Lee, JW; Park, BK | 1 |
Ali, I; Shabbir, M | 1 |
Bosman, N; Chibabhai, V; Lowman, W; Nana, T; Thomas, T | 1 |
Chopra, S; Das, S; Dasgupta, A; Karaulia, P; Pandey, AK; Pandey, M; Singh, AK; Soni, I; Thakare, R | 1 |
Amin, S; Dhrolia, MF; Mannan, A | 1 |
Anuset, D; Bernard, P; Durlach, A; Garval, E; Perceau, G; Vuiblet, V | 1 |
Castanheira, M; Flamm, RK; Pfaller, MA; Shortridge, D | 1 |
Bail, L; da Silva Nogueira, K; Dalmolin, TV; Ito, CAS; Martins, AF; Martins, AS; Rocha, JLL; Serio, AW; Tuon, FF | 1 |
Barkan, D; Grosfeld, T; Meir, M | 1 |
Chan, TF; Ip, M; Lau, TC; Lin, X; Lo, NW; Loo, J; Qin, H; Tsui, SK; Yim, AK | 1 |
Da Dalt, L; Guarnieri, M; Lucca, F; Muffato, G; Rigoli, R; Ros, M | 1 |
Guimbellot, JS; Poore, TS; Virella-Lowell, I | 1 |
Decousser, JW; Dowzicky, MJ; Fines-Guyon, M; Soussy, CJ; Woerther, PL | 1 |
Barber, KE; Bonomo, RA; Kaye, KS; Pogue, JM; Warnock, HD | 1 |
Attwood, M; Bowker, KE; MacGowan, AP; Noel, AR | 1 |
Burgess, DS; Campion, JJ; Feola, DJ; Kulengowski, B; Lee, GC; Rutter, WC | 1 |
Ejaz, A; Ejaz, H; Javed, H; Saleem, R; Younas, S; Zafar, A | 1 |
Burgess, DS; Clark, JA; Kulengowski, B | 1 |
Aguilera Xiol, E; Amaro, R; Antonelli, M; Artigas, A; Blasi, F; Bobi, J; Bringué, J; Carbonara, M; Chiurazzi, C; Comaru, T; Comino Trinidad, O; De Rosa, F; Fernandez-Barat, L; Fuster, C; Li Bassi, G; Marti, JD; Montgomery, AB; Motos, A; Nicolau, DP; Pelosi, P; Ramirez, J; Ranzani, OT; Rigol, M; Rinaudo, M; Saco, MA; Senussi, T; Torres, A; Yang, H | 1 |
Bošković, L; Božić, DD; Ivković, B; Milenković, M; Ušjak, D | 1 |
Alagna, R; Besozzi, G; Castellotti, P; Cirillo, D; Codecasa, L; De Lorenzo, S; Ferrarese, M; Mazzola, E; Riccardi, N; Saderi, L; Sotgiu, G; Udwadia, Z; Viggiani, P | 1 |
Dhareshwar, J; Gulia, S; Gupta, S; Kannan, RA; Rodrigues, C; Vora, A | 1 |
Boix Boix, AS; Brandariz Núñez, D; Gurri Hernand, FJ; Hernández Corredoira, V; Puig Forcada, J; Rodríguez Pedreira, P | 1 |
Chen, Y; Liu, L | 1 |
Mandal, J; Sugathan, S | 1 |
Fu, Y; Guo, Y; Li, C; Wang, Y; Yu, L; Zhang, J; Zhang, X; Zhao, J; Zhao, Y | 1 |
Antonelli, A; Cantón, R; Coppi, M; de Vogel, C; Gijón, D; Giske, CG; Hasan, B; Maruri, A; Rossolini, GM; Tellapragada, C; van Wamel, W; Verbon, A | 1 |
Bello, L; Caneiro, A; Gai, R; Galeano, S; Miller, A; Mosquera, R; Muxi, P; Oliver, AC; Pierri, S; Riva, E | 1 |
Aitken, SL; Gerges, B; Prince, RA; Raad, I; Rolston, KVI; Shelburne, S | 1 |
Pliska, NN | 1 |
Alves, LC; Brayner, FA; Firmo, EF; Lopes, ACS; Oliveira Júnior, JB; Scavuzzi, AML; Veras, DL | 1 |
Altun, B; Cakar, A; Demirci-Duarte, S; Eser, OK; Gur, D; Sancak, B; Unalan-Altintop, T | 1 |
Carvalhaes, CG; Castanheira, M; Doyle, TB; Sader, HS; Streit, JM | 1 |
Kaku, N; Ota, K; Yanagihara, K | 1 |
Alves, LC; Brayner, FA; Cavalcanti, CLB; da Rocha, DAM; da Silva, EM; Freitas, CF; Lima, FCG; Oliveira-Júnior, JB; Sandes, JM; Veras, DL | 1 |
Chen, Y; Du, Z; Liu, Y; Wang, Y; Yang, Z | 1 |
Bostrom, MP; Carli, AV; Levack, AE; Miller, AO; Turajane, K; Wellman, DS; Yang, X | 1 |
Piérard, D; Stone, GG | 1 |
Bostrom, MP; Carli, AV; Driscoll, DA; Levack, AE; Miller, AO; Turajane, K; Wellman, DS; Yang, X | 1 |
Bai, J; Ding, M; Li, Q; Liang, Q; Liang, S; Wang, G; Yan, X; Zhang, B; Zhang, F; Zhou, Y | 1 |
Gebrecherkos, T; Mekonnen, H; Molla Fenta, G; Seid, A | 1 |
Gunawan, C; Hamidian, M; Harmer, CJ; Mann, R; Rafei, R | 1 |
Daneman, N; Elligsen, M; Katz, K; Lam, PW; Lo, J; MacFadden, D; Teitelbaum, D; Vermeiren, C | 1 |
Alami, T; Benaouda, A; Bouchillon, SK; Karlowsky, JA; Mohamed, N; Sahm, DF; Soraa, N; Zerouali, K | 1 |
Ardebili, A; Bagheri, H; Goharrizi, MASB; Hjimohammadi, A; Izanloo, A; Jamali, A; Shahri, FN | 1 |
Bakkaloglu, Z; Demirbas, Z; Dizbay, M; Ozger, HS; Suzuk-Yildiz, S | 1 |
Atac, N; Baskurt, D; Berkkan, M; Can, F; Dogan, O; Guler, OU; Kilicoglu, BK; Ozer, B; Sever, E; Vatansever, C | 1 |
Ahmad, S; Ahmed, S; Ali, F; Farooq, M; Haq, I; Qureshi, SA; Rasheed, A; Sabir, MS; Shakeela, Q; Uzma, B | 1 |
Güler, N; Süleyman, A; Tamay, Z | 1 |
Blondeau, J; Lucaßen, K; Seifert, H; Utt, EA | 1 |
Antonelli, A; Cantón, R; Coppi, M; de Vogel, C; Frimodt-Møller, N; Gijón, D; Giske, CG; Hasan, B; Kragh, KN; Maruri, A; Morecchiato, F; Rossolini, GM; Tellapragada, C; van Wamel, W; Verbon, A | 1 |
Assenga, EN; Godfrey, E; Majaliwa, E | 1 |
Chen, J; Liu, W; Zhao, F | 1 |
Bai, Y; Fan, X; Fu, L; Tian, C; Wang, S; Xing, M; Zhao, Y | 1 |
Abousedu, YAI; Doghaim, M; Ghanem, OM; Sayer, F; Sayer, K | 1 |
A Katouah, H; Acker, M; Al Hadi, R; Ali, M; Alserihi, R; Alyami, J; Alzahrani, E; Amirazodi, M; Amrillah, T; Andreassen, OA; Ardiccioni, C; Ask, H; Atzori, C; Ayorech, Z; Azambuja, JH; Azmi, R; Badem, S; Balci, AB; Bali, H; Baranova, NS; Barantsevich, ER; Barocci, S; Bauer, RJ; Bauermeister, JA; Bazhenova, TA; Biagetti, G; Bigdeli, F; Bonar, EE; Bouloumis, T; Bu, Y; Cai, Z; Cakiroglu, B; Canetto, SS; Cao, J; Caucci, S; Cerbo, I; Chen, C; Chen, J; Chen, Q; Chen, Y; Cheng, B; Cheng, X; Chinappi, M; Choya, A; Cicconardi, F; Cipolletta, S; Colasurdo, G; Costabile, BK; Coughlin, LN; Crippa, P; D'Agostino, M; D'Annessa, I; Daryanoosh, F; Das, R; Davey Smith, G; Davidson, BR; Davies, NM; Davis, TME; Davis, WA; de Rivas, B; Demir, D; Deng, Z; Dhanya, TM; Di Marino, D; Divya, KM; Dong, N; Drinkwater, JJ; Ekholuenetale, M; El-Bindary, AA; El-Bindary, MA; El-Desouky, MG; Elsayed, H; Ema, K; Endraswari, PD; Entilli, L; Ettl, T; Eyado, A; Fan, X; Fang, W; Farina, M; Florimbio, AR; Fowobaje, KR; Gaeini, A; Gao, XM; Gao, Y; Ghaemi, R; Ghelardi, E; Gilmutdinov, IF; Gochicoa-Rangel, L; Goncu, MT; Gözüküçük, R; Grammatikopoulos, P; Gu, Y; Guan, ZJ; Gucu, A; Guldberg, R; Gungor, O; Guo, W; Gutiérrez-Ortiz, JI; Guzmán-Boulloud, N; Guzmán-Valderrábano, C; Głuszko, A; Hama, A; Hamada, M; Han, J; Hashimoto, T; Havdahl, A; Hayashita, T; He, X; Helgeland, Ø; Hinck, AP; Hinck, CS; Holtzapple, M; Hou, Y; Howe, LD; Hu, B; Hu, H; Huang, L; Huang, Z; Hughes, AM; Hussain, G; Ibidoja, OJ; Ichikawa, D; Imber, C; Islam, MR; Iype, S; Jaber, J; Jacobs, R; Jafry, AT; Ji, L; Ji, X; Jiang, L; Jiang, Y; Jie, HFM; Jie, HM; Johansen, MP; Johansson, S; Juan, LX; Juan, W; Kahraman, N; Kallinger, I; Kang, H; Karakulova, YV; Kärmer, T; Kataoka, S; Kato, K; Kawashima, N; Kazim, AH; Khalil, MR; Kitazawa, H; Klimesova, YM; Kojima, S; Kose, M; Kostakis, ID; Koushkie Jahromi, M; Krishna, GA; Krizova, D; La Teana, A; Lan, K; Li, J; Li, JZ; Li, M; Li, R; Li, S; Li, Y; Li, Z; Liu, H; Liu, J; Liu, KG; Liu, L; Liu, Q; Liu, T; Liu, X; Lomachenko, KA; López-Fonseca, R; Ludwig, N; Luo, A; Luo, L; Luo, Y; Lupetti, A; M El-Metwaly, N; Ma, K; Maemura, R; Magnus, P; Manakin, YV; Mancia, F; Mashood, LO; Matsumoto, K; Mehrabi, A; Meier, JK; Mekonnen, Y; Mencarelli, D; Menzo, S; Mikagi, A; Mironov, VS; Misawa-Suzuki, T; Miwata, S; Mizuta, Y; Mohanan, PV; Mondal, J; Morici, P; Morita, K; Morozzo Della Rocca, B; Morris, T; Morsali, A; Morzhukhina, MV; Motta, S; Muramatsu, H; Naidu, R; Narita, A; Narita, K; Nasralla, D; Nemcokova, M; Netukova, M; Nishikawa, E; Nishio, N; Niu, X; Niu, Y; Njølstad, P; Notarstefano, V; Nugroho, MA; Nørgård, BM; Okuno, Y; Olokede, O; Ong, SP; Osailan, A; Ouyang, Z; Ozyazicioglu, AF; Pan, F; Parui, A; Paul, R; Pavoni, E; Payne, TE; Peng, X; Pérez-Padilla, R; Perta, N; Peter, SC; Pierantoni, L; Pietrowska, M; Pissanou, T; Pollok, JM; Prasetio, A; Putra, FS; Qiang, C; Qiao, L; Qutob, HMH; Raptis, DA; Razzo, BM; Reichborn-Kjennerud, T; Reichert, TE; Remigio-Luna, A; Rexha, J; Rivani, E; Rizzato, C; Romagnoli, A; Rossolini, GM; Sa, LY; Saad, RA; Sakaguchi, H; Salesi, M; Salsabilla, Z; Sanderson, E; Sanderson, P; Savitha, DP; Schulz, D; Seker, IB; Selvaganapathy, PR; Sha, D; Shah, SF; Shaikhomar, OA; Sharma, D; Shi, C; Shi, P; Shrotri, A; Sidiq, DH; Simonov, SV; Singh, AK; Song, C; Song, T; Spanier, G; Spoerl, S; Staropoli, A; Statsenko, ME; Steinhauer, S; Stosic, A; Studeny, P; Sugaya, T; Sun, S; Sun, X; Sunbul, SA; Supandi, AR; Suzuki, K; Suzuki, Y; Szczepański, MJ; Takahashi, Y; Taniguchi, R; Tao, Y; Tesli, M; Thirión-Romero, I; Tong, D; Trucchi, E; Tsuchido, Y; Turchetti, C; Turkina, SV; Turner, AW; Uldbjerg, N; Vinale, F; Wakamatsu, M; Walton, MA; Wang, C; Wang, Q; Wang, W; Wang, Y; Wang, Z; Wehberg, S; Wei, ZL; Wen, B; Whiteside, TL; Whittingham, MS; Widodo, ADW; Widłak, P; Wright, AI; Wu, H; Wu, Y; Wu, YL; Xiang, LG; Xiao, G; Xie, B; Xie, L; Xin, H; Xiong, J; Xiong, X; Xu, C; Xu, S; Yagubskii, EB; Yakushev, IA; Yang, H; Yang, J; Yao, J; Yao, ZX; Ye, J; Yerneni, SS; Yirgu, A; Yoshida, N; Yoshida, T; Young, SD; Yu, DN; Yuksel, A; Zac, J; Zac, S; Zarifkar, AH; Zhai, Y; Zhang, F; Zhang, H; Zhang, JW; Zhang, L; Zhang, Q; Zhang, X; Zhang, Y; Zhao, D; Zhao, J; Zhao, M; Zheng, D; Zheng, J; Zhou, G; Zhou, H; Zhu, P; Zhu, T; Zhu, Y; Zimmerman, MA; Zou, X | 1 |
Caljon, B; Crombé, F; De Geyter, D; Demuyser, T; Janssen, T; Muyldermans, A; Piérard, D; Seyler, L; Vanstokstraeten, R; Wybo, I | 1 |
Jia, L; Jiang, Y; Li, X; Peng, Z; Wang, Y | 1 |
Fang, W; Liu, W; Song, L; Sun, W; Wang, C | 1 |
Artigas, A; Battaglini, D; Bobi, J; Cabrera, R; Camprubí-Rimblas, M; Fernández-Barat, L; Ferrer-Segarra, A; Frigola, G; Kiarostami, K; Li Bassi, G; Martinez, D; Meli, A; Motos, A; Nicolau, DP; Pagliara, F; Pelosi, P; Rigol, M; Torres, A; Vila, J; Yang, H; Yang, M | 1 |
Gales, AC; Sahm, DF; Stone, G; Utt, E; Wise, MG | 1 |
Chen, Y; Luo, H; Xu, L | 1 |
Chen, WT; DeRyke, CA; Karlowsky, JA; Lob, SH; Motyl, MR; Sahm, DF; Siddiqui, F; Young, K | 1 |
Abdellatif, GR; Aboshanab, KM; Mabrouk, SS; Zaid, ASA | 1 |
Adeleke, G; Egbagbe, E; Ejembi, J; Ettu, AO; Habib, A; Irowa, OO; Makanjuola, OB; Medugu, N; Mutiu, B; Ogunbosi, B; Ogunsola, F; Oladele, RO; Osinaike, T; Rotimi, V; Uwaezuoke, NS | 1 |
Bayatinejad, G; Beigverdi, R; Emaneini, M; Halimi, S; Jabalameli, F; Salehi, M | 1 |
Alves, LC; Bezerra Cavalcanti, CL; Brayner, FA; da Silva, EM; de Araújo, AR; de Freitas, CF; de Lima, FCG; do Nascimento, AV; Oliveira Júnior, JB; Sandes, JM; Veras, DL | 1 |
11 review(s) available for amikacin and meropenem
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Acute necrotizing gastritis by Escherichia coli in a severely neutropenic patient.
Topics: Acute Disease; Amikacin; Anemia, Aplastic; Antilymphocyte Serum; Combined Modality Therapy; Cyclosporine; Drug Therapy, Combination; Escherichia coli Infections; Gastric Mucosa; Gastritis; Granulocyte Colony-Stimulating Factor; Immunosuppressive Agents; Meropenem; Methylprednisolone; Necrosis; Neutropenia; Omeprazole; Parenteral Nutrition, Total; T-Lymphocytes; Thienamycins | 2002 |
Conservative treatment of prosthetic valve endocarditis due to Mycobacterium fortuitum.
Topics: Aged; Amikacin; Anti-Bacterial Agents; Ciprofloxacin; Endocarditis, Bacterial; Heart Valve Prosthesis; Humans; Male; Meropenem; Mycobacterium fortuitum; Mycobacterium Infections; Prosthesis-Related Infections; Thienamycins | 2002 |
Fulminant Listeria monocytogenes meningitis complicated with acute hydrocephalus in healthy children beyond the newborn period.
Topics: Acute Disease; Amikacin; Cefotaxime; Child; Child, Preschool; Combined Modality Therapy; Costa Rica; Dexamethasone; Drug Resistance; Drug Therapy, Combination; Emergencies; Fatal Outcome; Female; Humans; Hydrocephalus; Male; Meningitis, Listeria; Meropenem; Rifampin; Thienamycins; Tomography, X-Ray Computed; Vancomycin; Ventriculostomy | 2004 |
Septic arthritis due to extended spectrum beta lactamase producing Klebsiella pneumoniae.
Topics: Aged; Amikacin; Anti-Bacterial Agents; Arthritis, Infectious; beta-Lactamases; Female; Humans; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Middle Aged; Risk Factors; Thienamycins | 2007 |
Cerebral abscess caused by Serratia marcescens in a premature neonate.
Topics: Amikacin; Anti-Bacterial Agents; Brain Abscess; Diseases in Twins; Humans; Infant, Newborn; Male; Meropenem; Serratia Infections; Serratia marcescens; Thienamycins | 2007 |
Were all carbapenemases created equal? Treatment of NDM-producing extensively drug-resistant Enterobacteriaceae: a case report and literature review.
Topics: Amikacin; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Child; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Female; Humans; Meropenem; Serratia Infections; Serratia marcescens; Thienamycins; Treatment Outcome | 2018 |
Meta-analysis: combination of meropenem vs ceftazidime and amikacin for empirical treatment of cancer patients with febrile neutropenia.
Topics: Amikacin; Anti-Bacterial Agents; Ceftazidime; Drug Therapy, Combination; Febrile Neutropenia; Humans; Meropenem; Neoplasms | 2021 |
Brain Abscesses Caused by Nocardia farcinica in a 44-Year Old Woman with Multiple Myeloma: A Rare Case and Review of the Literature.
Topics: Adult; Amikacin; Antineoplastic Agents; Bortezomib; Brain Abscess; Female; Humans; Immunoglobulin G; Lenalidomide; Meropenem; Multiple Myeloma; Nocardia; Nocardia Infections; Trimethoprim, Sulfamethoxazole Drug Combination | 2022 |
Impact of dexamethasone and tocilizumab on hematological parameters in COVID-19 patients with chronic disease.
Topics: Acetaminophen; Acetylcarnitine; Acetylcholinesterase; Acids; Acinetobacter baumannii; Acinetobacter Infections; Adaptation, Psychological; Adolescent; Adsorption; Adult; Aged; Alcohol Drinking; Alzheimer Disease; Amikacin; Ammonia; Anaerobiosis; Animals; Anorexia; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Anxiety; Aptamers, Nucleotide; Asthenia; Attention Deficit Disorder with Hyperactivity; Bacterial Proteins; Beryllium; beta-Lactamases; Biofuels; Biomass; Biosensing Techniques; Bismuth; Blister; Body Mass Index; Body Surface Area; Boronic Acids; Brain; Breast Neoplasms; Butyrylcholinesterase; Cannabis; Carbapenems; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Carboxylic Acids; Carcinoma, Hepatocellular; Cardiovascular Diseases; Carnitine; Case-Control Studies; Catalysis; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Child; China; Cholinesterase Inhibitors; Clarithromycin; Clostridioides; Clostridioides difficile; Clostridium Infections; Cohort Studies; Colistin; Colitis; Colon; Coloring Agents; Coronary Artery Bypass; Creatinine; Crystalloid Solutions; Cytokines; Depression; Dextran Sulfate; Dextrans; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Diarrhea; Dietary Supplements; Diphenhydramine; Disease Models, Animal; Disease Outbreaks; Double-Blind Method; Doxorubicin; Drosophila; Drug Tapering; Dysbiosis; Electrons; Escherichia coli; Extracellular Vesicles; Fatigue; Female; Fermentation; gamma-Cyclodextrins; Gastrointestinal Microbiome; Glucose; Graft Survival; Graft vs Host Disease; Head and Neck Neoplasms; Heart Arrest, Induced; Hematopoietic Stem Cell Transplantation; High-Intensity Interval Training; Hippocampus; Humans; Hydrogen-Ion Concentration; Hypertension; Incidence; Interferon-gamma; Italy; Kinetics; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Lactoferrin; Larva; Length of Stay; Lignin; Liver; Liver Neoplasms; Liver Transplantation; Living Donors; Low Back Pain; Lung; Lung Volume Measurements; Macrophages; Male; Melphalan; Men; Mendelian Randomization Analysis; Meropenem; Methane; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Mitochondrial Proteins; Molecular Docking Simulation; Molecular Structure; Mothers; Motivation; Mycoplasma; Mycoplasma hominis; Mycoplasma Infections; NAD; Nanocomposites; Nanoparticles; Nanotubes, Carbon; Naproxen; Neovascularization, Pathologic; Neurons; Nitrates; Nucleolin; Opuntia; Paratyphoid Fever; Phenotype; Phosphatidylinositol 3-Kinases; Phytochemicals; Plant Extracts; Pregnancy; Prevalence; Prospective Studies; Proto-Oncogene Proteins c-akt; Pulmonary Disease, Chronic Obstructive; Rats; Rats, Wistar; Resveratrol; Retrospective Studies; Rifampin; Risk Factors; RNA, Messenger; Selenium; Sleep; Social Behavior; Soil; Soil Pollutants; Squamous Cell Carcinoma of Head and Neck; Staphylococcus aureus; Structure-Activity Relationship; Suicidal Ideation; Suicide; Superoxide Dismutase-1; Surveys and Questionnaires; Swimming; Syndrome; Tannins; Temperature; Transforming Growth Factor beta; Transplantation Conditioning; Treatment Outcome; Triple Negative Breast Neoplasms; Troponin T; Tumor Microenvironment; United Kingdom; Ureaplasma; Ureaplasma urealyticum; Urinary Tract Infections; Viscum; Waste Disposal Facilities; Wastewater; Water; Water Pollutants, Chemical; Wolfiporia; Young Adult | 2022 |
Drug resistance and susceptibility of amikacin in children with extended-spectrum beta-lactamase-producing Enterobacterales: a systematic review with meta-analysis.
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactamases; Child; Drug Resistance; Ertapenem; Escherichia coli; Humans; Imipenem; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Tigecycline | 2023 |
19 trial(s) available for amikacin and meropenem
Article | Year |
---|---|
In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
Topics: Anti-Bacterial Agents; Cephalosporins; Enterobacteriaceae; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Skin Diseases, Bacterial; Staphylococcus | 2008 |
Empirical monotherapy with meropenem in serious bacterial infections. Meropenem Study Group.
Topics: Adolescent; Adult; Aged; Amikacin; Bacterial Infections; Carbapenems; Ceftazidime; Community-Acquired Infections; Cross Infection; Drug Therapy, Combination; Drug Tolerance; Hospitalization; Humans; Meropenem; Middle Aged; Respiratory Tract Infections; Sepsis; Thienamycins; Time Factors; Treatment Outcome; Urinary Tract Infections | 1995 |
Safety and efficacy of meropenem in patients with septicaemia: a randomised comparison with ceftazidime, alone or combined with amikacin.
Topics: Adult; Aged; Amikacin; Carbapenems; Ceftazidime; Drug Therapy, Combination; Drug Tolerance; Hospitalization; Humans; Meropenem; Middle Aged; Sepsis; Thienamycins; Treatment Outcome | 1995 |
Safety and efficacy of meropenem in hospitalised children: randomised comparison with cefotaxime, alone and combined with metronidazole or amikacin. Meropenem Paediatric Study Group.
Topics: Amikacin; Anti-Bacterial Agents; Bacterial Infections; Carbapenems; Cefotaxime; Cephalosporins; Child; Child, Preschool; Drug Therapy, Combination; Drug Tolerance; Humans; Infant; Meropenem; Metronidazole; Thienamycins | 1995 |
Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research
Topics: Adolescent; Adult; Aged; Agranulocytosis; Amikacin; Ceftazidime; Child; Child, Preschool; Drug Therapy, Combination; Fever; Humans; Infant; Meropenem; Middle Aged; Neoplasms; Prospective Studies; Thienamycins | 1996 |
[Multicenter open randomized trial of meropenem in comparison to ceftazidime and amikacin used in combination in severe hospital infections].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amikacin; Ceftazidime; Cross Infection; Drug Therapy, Combination; Female; Humans; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Thienamycins; Treatment Outcome | 1998 |
Meropenem monotherapy versus combination therapy with ceftazidime and amikacin for empirical treatment of febrile neutropenic patients.
Topics: Adolescent; Adult; Aged; Amikacin; Anti-Bacterial Agents; Bacteremia; Bacterial Infections; Ceftazidime; Cephalosporins; Drug Therapy, Combination; Female; Fever; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Male; Meropenem; Middle Aged; Neutropenia; Thienamycins | 1998 |
[Comparative study of meropenem and amikacin/metronidazole combination in the treatment of severe abdominal surgical infections].
Topics: Abdomen; Amikacin; Drug Combinations; Humans; Meropenem; Metronidazole; Surgical Wound Infection; Thienamycins | 1998 |
Comparison of meropenem with amikacin plus ceftazidime in the empirical treatment of febrile neutropenia: a prospective randomised multicentre trial in patients without previous prophylactic antibiotics. Meropenem Study Group of Turkey.
Topics: Adult; Amikacin; Antibiotic Prophylaxis; Ceftazidime; Drug Therapy, Combination; Female; Fever; Humans; Male; Meropenem; Middle Aged; Neutropenia; Prospective Studies; Thienamycins; Treatment Outcome | 1999 |
Efficacy of meropenem as monotherapy in the treatment of ventilator-associated pneumonia.
Topics: Aged; Amikacin; Analysis of Variance; Ceftazidime; Drug Therapy, Combination; Female; Humans; Male; Meropenem; Middle Aged; Odds Ratio; Pneumonia, Bacterial; Prospective Studies; Respiration, Artificial; Thienamycins; Treatment Outcome | 2001 |
Cost-effectiveness of cefepime + netilmicin or ceftazidime + amikacin or meropenem monotherapy in febrile neutropenic children with malignancy in Turkey.
Topics: Adolescent; Adult; Amikacin; Cefepime; Cephalosporins; Child; Child, Preschool; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Fever; Humans; Infant; Male; Meropenem; Neoplasms; Netilmicin; Neutropenia; Prospective Studies; Thienamycins; Turkey | 2001 |
[Efficacy of monotherapy by meropenem in ventilator-associated pneumonia].
Topics: Amikacin; Ceftazidime; Cross Infection; Drug Therapy, Combination; Female; Humans; Male; Meropenem; Middle Aged; Pneumonia, Bacterial; Prospective Studies; Respiration, Artificial; Superinfection; Thienamycins | 2001 |
Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empirical therapy for neutropenic fever in children with malignancy.
Topics: Adolescent; Amikacin; Anti-Bacterial Agents; Ceftazidime; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Diarrhea; Drug Therapy, Combination; Female; Fever; Gram-Negative Bacteria; Gram-Positive Cocci; Hospitals, University; Humans; Infant; Male; Meropenem; Neoplasms; Neutropenia; Taiwan; Thienamycins; Treatment Outcome | 2003 |
Meropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children.
Topics: Amikacin; Anti-Bacterial Agents; Drug Therapy, Combination; Fever; Fungi; Gram-Negative Bacteria; Gram-Positive Bacteria; Hematologic Neoplasms; Humans; Infections; Meropenem; Neoplasms; Netilmicin; Neutropenia; Penicillanic Acid; Piperacillin; Tazobactam; Thienamycins | 2004 |
Clinical experience with three combination regimens for the treatment of high-risk febrile neutropenia.
Topics: Adolescent; Adult; Aged; Amikacin; Anti-Bacterial Agents; Ceftazidime; Drug Therapy, Combination; Female; Fever; Humans; Immunocompromised Host; Male; Meropenem; Middle Aged; Neutropenia; Penicillanic Acid; Piperacillin; Prospective Studies; Risk Assessment; Risk Factors; Tazobactam; Thienamycins | 2006 |
[Clinical and bacteriological efficacy and tolerability of meropenem in the treatment of bronchopulmonary affections in children with mucoviscidosis].
Topics: Amikacin; Anti-Bacterial Agents; Bronchopneumonia; Child; Cystic Fibrosis; Drug Therapy, Combination; Female; Humans; Male; Meropenem; Thienamycins; Treatment Outcome | 2006 |
Population pharmacokinetics of four β-lactams in critically ill septic patients comedicated with amikacin.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Amikacin; Anti-Bacterial Agents; beta-Lactams; Cefepime; Ceftazidime; Cephalosporins; Critical Illness; Drug Monitoring; Female; Humans; Male; Meropenem; Metabolic Clearance Rate; Middle Aged; Models, Biological; Piperacillin; Sepsis; Thienamycins; Tissue Distribution; Treatment Outcome | 2012 |
Antibacterial activity of achievable epithelial lining fluid exposures of Amikacin Inhale with or without meropenem.
Topics: Administration, Inhalation; Adult; Aged; Amikacin; Anti-Bacterial Agents; Body Fluids; Female; Humans; Klebsiella pneumoniae; Male; Meropenem; Microbial Sensitivity Tests; Microbial Viability; Middle Aged; Pseudomonas aeruginosa; Thienamycins; Young Adult | 2016 |
Impact of dexamethasone and tocilizumab on hematological parameters in COVID-19 patients with chronic disease.
Topics: Acetaminophen; Acetylcarnitine; Acetylcholinesterase; Acids; Acinetobacter baumannii; Acinetobacter Infections; Adaptation, Psychological; Adolescent; Adsorption; Adult; Aged; Alcohol Drinking; Alzheimer Disease; Amikacin; Ammonia; Anaerobiosis; Animals; Anorexia; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Anxiety; Aptamers, Nucleotide; Asthenia; Attention Deficit Disorder with Hyperactivity; Bacterial Proteins; Beryllium; beta-Lactamases; Biofuels; Biomass; Biosensing Techniques; Bismuth; Blister; Body Mass Index; Body Surface Area; Boronic Acids; Brain; Breast Neoplasms; Butyrylcholinesterase; Cannabis; Carbapenems; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Carboxylic Acids; Carcinoma, Hepatocellular; Cardiovascular Diseases; Carnitine; Case-Control Studies; Catalysis; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Child; China; Cholinesterase Inhibitors; Clarithromycin; Clostridioides; Clostridioides difficile; Clostridium Infections; Cohort Studies; Colistin; Colitis; Colon; Coloring Agents; Coronary Artery Bypass; Creatinine; Crystalloid Solutions; Cytokines; Depression; Dextran Sulfate; Dextrans; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Diarrhea; Dietary Supplements; Diphenhydramine; Disease Models, Animal; Disease Outbreaks; Double-Blind Method; Doxorubicin; Drosophila; Drug Tapering; Dysbiosis; Electrons; Escherichia coli; Extracellular Vesicles; Fatigue; Female; Fermentation; gamma-Cyclodextrins; Gastrointestinal Microbiome; Glucose; Graft Survival; Graft vs Host Disease; Head and Neck Neoplasms; Heart Arrest, Induced; Hematopoietic Stem Cell Transplantation; High-Intensity Interval Training; Hippocampus; Humans; Hydrogen-Ion Concentration; Hypertension; Incidence; Interferon-gamma; Italy; Kinetics; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Lactoferrin; Larva; Length of Stay; Lignin; Liver; Liver Neoplasms; Liver Transplantation; Living Donors; Low Back Pain; Lung; Lung Volume Measurements; Macrophages; Male; Melphalan; Men; Mendelian Randomization Analysis; Meropenem; Methane; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Mitochondrial Proteins; Molecular Docking Simulation; Molecular Structure; Mothers; Motivation; Mycoplasma; Mycoplasma hominis; Mycoplasma Infections; NAD; Nanocomposites; Nanoparticles; Nanotubes, Carbon; Naproxen; Neovascularization, Pathologic; Neurons; Nitrates; Nucleolin; Opuntia; Paratyphoid Fever; Phenotype; Phosphatidylinositol 3-Kinases; Phytochemicals; Plant Extracts; Pregnancy; Prevalence; Prospective Studies; Proto-Oncogene Proteins c-akt; Pulmonary Disease, Chronic Obstructive; Rats; Rats, Wistar; Resveratrol; Retrospective Studies; Rifampin; Risk Factors; RNA, Messenger; Selenium; Sleep; Social Behavior; Soil; Soil Pollutants; Squamous Cell Carcinoma of Head and Neck; Staphylococcus aureus; Structure-Activity Relationship; Suicidal Ideation; Suicide; Superoxide Dismutase-1; Surveys and Questionnaires; Swimming; Syndrome; Tannins; Temperature; Transforming Growth Factor beta; Transplantation Conditioning; Treatment Outcome; Triple Negative Breast Neoplasms; Troponin T; Tumor Microenvironment; United Kingdom; Ureaplasma; Ureaplasma urealyticum; Urinary Tract Infections; Viscum; Waste Disposal Facilities; Wastewater; Water; Water Pollutants, Chemical; Wolfiporia; Young Adult | 2022 |
213 other study(ies) available for amikacin and meropenem
Article | Year |
---|---|
Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China.
Topics: beta-Lactam Resistance; beta-Lactamases; Carbapenems; China; Hospitals, University; Humans; Klebsiella pneumoniae; Molecular Sequence Data; Plasmids | 2007 |
Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis.
Topics: Anti-Bacterial Agents; Burkholderia cepacia complex; Burkholderia Infections; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Drug Synergism; Humans; Microbial Sensitivity Tests | 2007 |
Clinical prediction tool to identify patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk for multidrug resistance.
Topics: Adult; Anti-Bacterial Agents; Case-Control Studies; Drug Resistance, Multiple, Bacterial; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Predictive Value of Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Retrospective Studies; Risk; Risk Factors | 2007 |
Coproduction of novel 16S rRNA methylase RmtD and metallo-beta-lactamase SPM-1 in a panresistant Pseudomonas aeruginosa isolate from Brazil.
Topics: Amino Acid Sequence; Aminoglycosides; beta-Lactamases; Brazil; Carbapenems; Cloning, Molecular; Drug Resistance, Multiple, Bacterial; Methyltransferases; Microbial Sensitivity Tests; Molecular Sequence Data; Plasmids; Pseudomonas aeruginosa; Pseudomonas Infections | 2007 |
In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
Topics: Anti-Bacterial Agents; Humans; Microbial Sensitivity Tests; Minocycline; Nocardia; Nocardia Infections; Polymorphism, Restriction Fragment Length; Reverse Transcriptase Polymerase Chain Reaction; Tigecycline | 2007 |
First report of plasmid-mediated qnrA1 in a ciprofloxacin-resistant Escherichia coli strain in Latin America.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Conjugation, Genetic; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Integrons; Latin America; Molecular Sequence Data; Plasmids | 2007 |
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Drug Resistance, Bacterial; Humans; Longitudinal Studies; Pneumonia, Ventilator-Associated; Polymerase Chain Reaction; Pseudomonas aeruginosa; Pseudomonas Infections | 2007 |
First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase.
Topics: beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Hydrolysis; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2007 |
In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Anti-Infective Agents; Carbapenems; Drug Combinations; Drug Resistance, Bacterial; Microbial Sensitivity Tests; Minocycline; Tigecycline | 2007 |
Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
Topics: Aged; Anti-Bacterial Agents; beta-Lactamases; Community-Acquired Infections; Cross Infection; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Humans; Microbial Sensitivity Tests; Middle Aged; Portugal | 2007 |
Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Cross Infection; Drug Resistance, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Escherichia coli; Female; Humans; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Middle Aged; Predictive Value of Tests; Proteus mirabilis; Risk Factors; Survival Analysis; Treatment Outcome | 2007 |
Spread in an Italian hospital of a clonal Acinetobacter baumannii strain producing the TEM-92 extended-spectrum beta-lactamase.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Cross Infection; Humans; Italy; Microbial Sensitivity Tests | 2007 |
Effects of carbapenem exposure on the risk for digestive tract carriage of intensive care unit-endemic carbapenem-resistant Pseudomonas aeruginosa strains in critically ill patients.
Topics: Adult; Aged; Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Carrier State; Critical Illness; Endemic Diseases; Female; Gastrointestinal Tract; Humans; Imipenem; Incidence; Intensive Care Units; Male; Middle Aged; Pharynx; Pseudomonas aeruginosa; Pseudomonas Infections; Rectum; Risk Factors | 2007 |
blaVIM-2-harboring integrons isolated in India, Russia, and the United States arise from an ancestral class 1 integron predating the formation of the 3' conserved sequence.
Topics: Base Sequence; beta-Lactamases; DNA Transposable Elements; Evolution, Molecular; Genes, Bacterial; Humans; India; Integrons; Molecular Sequence Data; Pseudomonas aeruginosa; Russia; United States | 2007 |
Enterobacteriaceae bloodstream infections: presence of integrons, risk factors, and outcome.
Topics: Bacteremia; Community-Acquired Infections; Cross Infection; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Enterobacteriaceae Infections; Gene Transfer, Horizontal; Humans; Infectious Disease Transmission, Professional-to-Patient; Integrons; Microbial Sensitivity Tests; Nucleic Acid Amplification Techniques; Polymerase Chain Reaction; Prospective Studies; Risk Factors; Sequence Analysis, DNA; Treatment Outcome | 2007 |
Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
Topics: Acinetobacter; Amino Acid Sequence; Aminoglycosides; Anti-Bacterial Agents; Base Sequence; Brazil; Codon, Terminator; Cross Infection; Drug Resistance, Multiple, Bacterial; Gene Transfer, Horizontal; Genes, Bacterial; Hospitals; Humans; Integrons; Microbial Sensitivity Tests; Molecular Sequence Data; Open Reading Frames; Plasmids; Pseudomonas putida; Transcription, Genetic | 2007 |
First occurrence of an Escherichia coli clinical isolate producing the VIM-1/VIM-2 hybrid metallo-beta-lactamase VIM-12.
Topics: Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamases; Conjugation, Genetic; Escherichia coli; Escherichia coli Infections; Humans; Male; Microbial Sensitivity Tests; Plasmids; Recombination, Genetic | 2007 |
Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Hospitals; Humans; Israel; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Molecular Epidemiology | 2007 |
Colistin methanesulfonate against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamic model.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Ceftazidime; Colistin; Colony Count, Microbial; Drug Combinations; Drug Resistance, Multiple, Bacterial; Microbial Sensitivity Tests | 2007 |
Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
Topics: Bacterial Proteins; Base Sequence; beta-Lactamases; Carrier Proteins; Cloning, Molecular; DNA, Bacterial; Drug Resistance, Bacterial; Enterobacter cloacae; Enterobacteriaceae Infections; Genes, MDR; Genetic Vectors; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Plasmids; Porins | 2007 |
An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Bacterial Proteins; Base Sequence; beta-Lactamases; Drug Resistance, Bacterial; Electrophoresis, Gel, Two-Dimensional; Electrophoresis, Polyacrylamide Gel; Gene Expression Regulation, Bacterial; Humans; Imipenem; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sequence Homology, Nucleic Acid | 2007 |
Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
Topics: Acinetobacter; Acinetobacter Infections; Aminoglycosides; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Blotting, Southern; Carbapenems; China; Chloramphenicol; Colistin; Cross Infection; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Hospitals; Humans; Imipenem; Integrons; Microbial Sensitivity Tests; Molecular Epidemiology; Molecular Sequence Data; Rifampin; Sequence Analysis, DNA | 2007 |
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Chromosomes, Bacterial; Cross Infection; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Integrons; Molecular Epidemiology; Molecular Sequence Data; Mutation; Plasmids; Polymerase Chain Reaction; Porins; Pseudomonas aeruginosa; Sequence Analysis, DNA; Sequence Homology, Amino Acid; Spain | 2007 |
Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Europe; Humans; Latin America; Microbial Sensitivity Tests; Minocycline; North America; Population Surveillance; Tigecycline | 2008 |
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; beta-Lactamases; Canada; Drug Resistance, Bacterial; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Intensive Care Units; Male; Microbial Sensitivity Tests; Middle Aged; Population Surveillance | 2008 |
Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States.
Topics: Aged; Bacterial Proteins; Base Sequence; beta-Lactamases; DNA Primers; DNA, Bacterial; Drug Resistance, Bacterial; Genes, Bacterial; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Molecular Epidemiology; Plasmids; Quinolones; United States | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico.
Topics: Bacterial Proteins; beta-Lactamases; Cross Infection; Electrophoresis, Gel, Pulsed-Field; Humans; Integrons; Mexico; Models, Genetic; Molecular Sequence Data; Pseudomonas aeruginosa; Pseudomonas Infections | 2008 |
Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic.
Topics: Adult; Bacterial Proteins; beta-Lactamases; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Endemic Diseases; Escherichia coli; Escherichia coli Infections; Female; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Middle Aged; Polymerase Chain Reaction; Sequence Analysis, DNA; Thailand | 2008 |
Characterization of the carbapenem-hydrolyzing oxacillinase oxa-58 in an Acinetobacter genospecies 3 clinical isolate.
Topics: Acinetobacter; Acinetobacter Infections; Anti-Bacterial Agents; Bacterial Proteins; Base Sequence; beta-Lactamases; Carbapenems; Humans; Imipenem; Microbial Sensitivity Tests; Molecular Sequence Data; Plasmids; Sequence Analysis, DNA | 2008 |
Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.
Topics: Bacterial Proteins; beta-Lactamases; Carbapenems; Cross Infection; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Models, Genetic; Turkey | 2008 |
Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
Topics: Anti-Infective Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Ciprofloxacin; Drug Resistance, Bacterial; Enterobacter cloacae; Genes, Bacterial; Microbial Sensitivity Tests; Plasmids; Quinolones | 2008 |
Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
Topics: Carbapenems; Imipenem; Meropenem; Methicillin Resistance; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Staphylococcus aureus; Thienamycins | 2008 |
Bloodstream infections caused by extended-spectrum-beta-lactamase- producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Multivariate Analysis; Risk Factors; Treatment Failure | 2008 |
Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Bacterial Proteins; beta-Lactamases; Drug Resistance, Bacterial; Endemic Diseases; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; New York City; Sequence Analysis, DNA | 2008 |
Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; Base Sequence; beta-Lactam Resistance; beta-Lactamases; Cloning, Molecular; DNA Primers; DNA, Bacterial; Genes, Bacterial; Genetic Variation; Humans; Imipenem; Integrons; Kinetics; Meropenem; Molecular Sequence Data; Phylogeny; Pseudomonas aeruginosa; Pseudomonas Infections; Recombinant Proteins; Sequence Homology, Amino Acid; Spain; Thienamycins | 2008 |
A plasmid-borne blaOXA-58 gene confers imipenem resistance to Acinetobacter baumannii isolates from a Lebanese hospital.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Conjugation, Genetic; Cross Infection; Disease Outbreaks; Drug Resistance, Multiple, Bacterial; Genes, Bacterial; Hospitals, University; Humans; Imipenem; Lebanon; Molecular Epidemiology; Molecular Sequence Data; Plasmids | 2008 |
Genetic basis of multidrug resistance in Acinetobacter baumannii clinical isolates at a tertiary medical center in Pennsylvania.
Topics: Academic Medical Centers; Acinetobacter baumannii; Acinetobacter Infections; Amikacin; Base Sequence; beta-Lactamases; Cross Infection; DNA Primers; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Genes, Bacterial; Humans; Microbial Sensitivity Tests; Molecular Epidemiology; Pennsylvania; Polymerase Chain Reaction | 2008 |
Carbapenem-resistant Acinetobacter baumannii isolates expressing the blaOXA-23 gene associated with ISAba4 in Belgium.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Belgium; beta-Lactam Resistance; beta-Lactamases; Carbapenems; DNA Transposable Elements; Genes, Bacterial; Humans | 2008 |
High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
Topics: Acetyltransferases; Anti-Bacterial Agents; Bacterial Proteins; China; Conjugation, Genetic; Drug Resistance, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Hospitals, Teaching; Humans; Microbial Sensitivity Tests; Plasmids; Polymerase Chain Reaction; Prevalence; Quinolones | 2008 |
First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
Topics: Base Sequence; beta-Lactam Resistance; beta-Lactamases; Data Collection; DNA Primers; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Genes, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Integrons; Italy; Molecular Epidemiology; Molecular Sequence Data | 2008 |
KPC-2-producing Enterobacter cloacae and pseudomonas putida coinfection in a liver transplant recipient.
Topics: Anti-Bacterial Agents; beta-Lactamases; Enterobacter cloacae; Female; Humans; Liver Transplantation; Microbial Sensitivity Tests; Middle Aged; Pseudomonas putida; RNA, Ribosomal, 16S | 2009 |
Detection of the pandemic O25-ST131 human virulent Escherichia coli CTX-M-15-producing clone harboring the qnrB2 and aac(6')-Ib-cr genes in a dog.
Topics: Animals; Anti-Bacterial Agents; Dogs; Drug Resistance, Bacterial; Escherichia coli; Genes, Bacterial; Humans; Plasmids; Virulence | 2009 |
Codetection of blaOXA-23-like gene (blaOXA-133) and blaOXA-58 in Acinetobacter radioresistens: report from the SENTRY antimicrobial surveillance program.
Topics: Acinetobacter; Anti-Bacterial Agents; beta-Lactamases; Drug Resistance, Bacterial; Molecular Sequence Data; Plasmids; Population Surveillance; Reverse Transcriptase Polymerase Chain Reaction; Transcription, Genetic | 2009 |
Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18).
Topics: Anti-Bacterial Agents; Bacterial Proteins; Base Sequence; beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Humans; India; Microbial Sensitivity Tests; Molecular Sequence Data; Prevalence; Pseudomonas aeruginosa; Ribotyping | 2009 |
blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures.
Topics: Base Sequence; beta-Lactamases; DNA Transposable Elements; Escherichia coli; Molecular Sequence Data; Plasmids; Polymerase Chain Reaction | 2009 |
First organisms with acquired metallo-beta-lactamases (IMP-13, IMP-22, and VIM-2) reported in Austria.
Topics: Austria; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Pseudomonas aeruginosa; Pseudomonas Infections; Sequence Analysis, DNA | 2009 |
Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; DNA Transposable Elements; Drug Resistance, Bacterial; Hospitals, Urban; Humans; Isoenzymes; Klebsiella Infections; Klebsiella oxytoca; Klebsiella pneumoniae; Microbial Sensitivity Tests; New York City; Plasmids; Transposases | 2009 |
In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; beta-Lactamases; Ceftaroline; Cephalosporins; Drug Combinations; Drug Resistance, Bacterial; Drug Synergism; Enterobacteriaceae; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2009 |
AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates.
Topics: Acetylation; Acetyltransferases; Aminoglycosides; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Humans; Integrons; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2009 |
Characterization of pABVA01, a plasmid encoding the OXA-24 carbapenemase from Italian isolates of Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Genotype; Microbial Sensitivity Tests; Molecular Sequence Data; Open Reading Frames; Plasmids; Sequence Analysis, DNA | 2009 |
Diversity of beta-lactamases produced by ceftazidime-resistant Pseudomonas aeruginosa isolates causing bloodstream infections in Brazil.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Brazil; Carbapenems; Ceftazidime; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolones | 2009 |
Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Poland.
Topics: Anti-Bacterial Agents; beta-Lactamases; Drug Resistance, Multiple, Bacterial; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Middle Aged; Molecular Sequence Data; Poland | 2009 |
Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China.
Topics: Anti-Bacterial Agents; beta-Lactamases; Blotting, Southern; Carbapenems; China; Electrophoresis, Gel, Pulsed-Field; Enterobacteriaceae; Microbial Sensitivity Tests; Polymerase Chain Reaction | 2009 |
Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
Topics: beta-Lactamases; Computational Biology; Escherichia coli; Models, Genetic; Molecular Sequence Data; Open Reading Frames; Plasmids; United Kingdom | 2009 |
Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain.
Topics: Anti-Bacterial Agents; Base Sequence; beta-Lactamases; Colistin; Cross Infection; Humans; Molecular Sequence Data; Pseudomonas aeruginosa | 2009 |
Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain.
Topics: Amikacin; Aminoglycosides; Anti-Bacterial Agents; beta-Lactamases; Cefepime; Cephalosporins; Clavulanic Acid; Gentamicins; Humans; Imipenem; Integrons; Meropenem; Molecular Sequence Data; Penicillanic Acid; Piperacillin; Plasmids; Pseudomonas aeruginosa; Pseudomonas Infections; Spain; Tazobactam; Thienamycins | 2009 |
Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; Drug Resistance, Multiple, Bacterial; Escherichia coli; Membrane Transport Proteins; Microbial Sensitivity Tests; Molecular Sequence Data; Sequence Homology, Amino Acid | 2009 |
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
Topics: Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Bacterial Proteins; beta-Lactamases; Carbapenems; China; Cross Infection; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Enterobacteriaceae; Enterobacteriaceae Infections; Genotype; Integrons; Microbial Sensitivity Tests; Phenotype; Population Surveillance; Porins; Reverse Transcriptase Polymerase Chain Reaction | 2010 |
First isolation of the blaOXA-23 carbapenemase gene from an environmental Acinetobacter baumannii isolate.
Topics: Acinetobacter baumannii; beta-Lactamases; DNA, Bacterial; Escherichia coli; France; Genes, Bacterial; Water Microbiology | 2010 |
Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Isoelectric Focusing; Microbial Sensitivity Tests; Polymerase Chain Reaction; Pseudomonas aeruginosa; Pseudomonas Infections | 2010 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Proteins; Cations, Monovalent; Culture Media; Drug Resistance, Bacterial; Gene Expression Profiling; Gene Expression Regulation, Bacterial; Humans; Microbial Sensitivity Tests; Oligonucleotide Array Sequence Analysis; Proteomics; Sodium Chloride; Virulence Factors | 2010 |
Detection of KPC in Acinetobacter spp. in Puerto Rico.
Topics: Acinetobacter; Acinetobacter Infections; Adult; Aged; Aged, 80 and over; beta-Lactam Resistance; beta-Lactamases; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Population Surveillance; Puerto Rico | 2010 |
Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Topics: Bacterial Outer Membrane Proteins; Bacterial Proteins; beta-Lactamases; Cystic Fibrosis; Drug Resistance, Bacterial; Drug Resistance, Multiple; Electrophoresis, Gel, Pulsed-Field; Humans; Membrane Transport Proteins; Mutation; Porins; Pseudomonas aeruginosa; Pseudomonas Infections; Reverse Transcriptase Polymerase Chain Reaction; Up-Regulation | 2010 |
Genetic basis of multidrug resistance in Acinetobacter clinical isolates in Taiwan.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Aminoglycosides; beta-Lactamases; Carbapenems; Cephalosporins; DNA Gyrase; Drug Resistance, Bacterial; Drug Resistance, Multiple; Fluoroquinolones; Humans; Taiwan | 2010 |
Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Ciprofloxacin; Clinical Trials, Phase III as Topic; Doripenem; Enterobacteriaceae; Enterobacteriaceae Infections; Global Health; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prevalence | 2010 |
Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
Topics: Academic Medical Centers; Bacterial Proteins; Base Sequence; beta-Lactamases; Carbapenems; DNA Primers; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Escherichia coli; Escherichia coli Infections; Humans; In Vitro Techniques; Israel; Microbial Sensitivity Tests; Molecular Epidemiology; Plasmids; Time Factors | 2010 |
Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
Topics: Bacterial Proteins; beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Humans; Israel; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Molecular Epidemiology; Phylogeny; Plasmids; Polymerase Chain Reaction | 2010 |
Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
Topics: Acinetobacter; Acinetobacter Infections; beta-Lactam Resistance; beta-Lactamases; Cephalosporinase; Gene Transfer, Horizontal; Genes, Bacterial; Humans; In Vitro Techniques; Integrons; Microbial Sensitivity Tests; Molecular Epidemiology; Molecular Sequence Data; Phylogeny; Taiwan | 2010 |
In vitro activity of the aminoglycoside antibiotic arbekacin against Acinetobacter baumannii-calcoaceticus isolated from war-wounded patients at Walter Reed Army Medical Center.
Topics: Acinetobacter baumannii; Aminoglycosides; Anti-Bacterial Agents; Carbapenems; Dibekacin; Hospitals, Military; Humans; Microbial Sensitivity Tests; Warfare | 2010 |
First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
Topics: Anti-Bacterial Agents; beta-Lactamases; Ceftazidime; Drug Resistance, Bacterial; Germany; Hospitals, University; Humans; Imipenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2010 |
Complete nucleotide sequence of Klebsiella pneumoniae multidrug resistance plasmid pKP048, carrying blaKPC-2, blaDHA-1, qnrB4, and armA.
Topics: Aminoglycosides; Anti-Bacterial Agents; Base Sequence; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Klebsiella pneumoniae; Models, Genetic; Molecular Sequence Data; Plasmids | 2010 |
In vitro antimicrobial activity and mutant prevention concentration of colistin against Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Colistin; Drug Resistance, Multiple, Bacterial; Microbial Sensitivity Tests; Mutation | 2010 |
Frequency of spontaneous resistance to fosfomycin combined with different antibiotics in Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Fosfomycin; Mutation; Pseudomonas aeruginosa | 2010 |
Emergence and Distribution of Plasmids Bearing the blaOXA-51-like gene with an upstream ISAba1 in carbapenem-resistant Acinetobacter baumannii isolates in Taiwan.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Proteins; Blotting, Southern; Carbapenems; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Molecular Sequence Data; Plasmids; Taiwan | 2010 |
Antimicrobial resistance testing of verocytotoxin-producing Escherichia coli and first description of TEM-52 extended-spectrum β-lactamase in serogroup O26.
Topics: Adhesins, Bacterial; Anti-Bacterial Agents; beta-Lactamases; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Proteins; Humans; Plasmids; Shiga Toxins | 2010 |
Microbiologic and clinical implications of bacteremia due to extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae with or without plasmid-mediated AmpC beta-lactamase DHA-1.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Bacterial Proteins; beta-Lactamases; Carbapenems; Case-Control Studies; Ciprofloxacin; Female; Humans; Klebsiella pneumoniae; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Plasmids; Young Adult | 2010 |
In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Bacterial Proteins; Carbapenems; Drug Resistance, Bacterial; Fatal Outcome; Humans; Male; Middle Aged; Molecular Sequence Data; Mutation, Missense; Reverse Transcriptase Polymerase Chain Reaction | 2010 |
Pyridone-conjugated monobactam antibiotics with gram-negative activity.
Topics: Animals; Anti-Bacterial Agents; Escherichia coli; Gram-Negative Bacteria; Inhibitory Concentration 50; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Molecular Structure; Monobactams; Pseudomonas aeruginosa; Pyridones; Rats; Rats, Wistar | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Design, Synthesis, and Biological Evaluation of Hexacyclic Tetracyclines as Potent, Broad Spectrum Antibacterial Agents.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Drug Design; Female; Humans; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Pseudomonas aeruginosa; Pseudomonas Infections; Structure-Activity Relationship; Tetracyclines; Thigh | 2015 |
Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
Topics: Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; Moxifloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2016 |
Heterocyclyl Tetracyclines. 1. 7-Trifluoromethyl-8-Pyrrolidinyltetracyclines: Potent, Broad Spectrum Antibacterial Agents with Enhanced Activity against Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Halogenation; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Pyrrolidinones; Tetracycline Resistance; Tetracyclines | 2017 |
Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
Topics: Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Positive Bacteria; Hemolysis; Lysine; Microbial Sensitivity Tests; Minocycline; Models, Biological; Rifampin; Tobramycin | 2017 |
Design, Synthesis, and Properties of a Potent Inhibitor of Pseudomonas aeruginosa Deacetylase LpxC.
Topics: Amidohydrolases; Animals; Anti-Bacterial Agents; Chemistry Techniques, Synthetic; Crystallography, X-Ray; Drug Design; Drug Evaluation, Preclinical; Drug Resistance, Multiple, Bacterial; Enzyme Inhibitors; Female; Hep G2 Cells; Humans; K562 Cells; Mice, Inbred BALB C; Microbial Sensitivity Tests; Molecular Docking Simulation; Pseudomonas aeruginosa; Pseudomonas Infections; Structure-Activity Relationship | 2017 |
Microwave-assisted solid-phase synthesis of antisense acpP peptide nucleic acid-peptide conjugates active against colistin- and tigecycline-resistant E. coli and K. pneumoniae.
Topics: Anti-Bacterial Agents; Colistin; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Escherichia coli; Klebsiella pneumoniae; Microbial Sensitivity Tests; Microwaves; Molecular Structure; Peptide Nucleic Acids; Peptides; Solid-Phase Synthesis Techniques; Structure-Activity Relationship; Tigecycline | 2019 |
Design, synthesis, and biological evaluation of 3-amino-2-oxazolidinone derivatives as potent quorum-sensing inhibitors of Pseudomonas aeruginosa PAO1.
Topics: Anti-Bacterial Agents; Biofilms; Dose-Response Relationship, Drug; Drug Design; Microbial Sensitivity Tests; Molecular Structure; Oxazolidinones; Pseudomonas aeruginosa; Quorum Sensing; Structure-Activity Relationship | 2020 |
Comparative activity of meropenem (SM-7338) against major respiratory pathogens and amikacin-resistant nosocomial isolates.
Topics: Amikacin; Bacteria; Cross Infection; Drug Resistance, Microbial; Humans; Meropenem; Microbial Sensitivity Tests; Respiratory Tract Infections; Thienamycins | 1992 |
Bacteriostatic and bactericidal in-vitro activity of meropenem against clinical isolates, including Mycobacterium avium complex.
Topics: Amikacin; Bacteria; Bacterial Infections; Carbapenems; Drug Synergism; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Meropenem; Microbial Sensitivity Tests; Mycobacterium avium Complex; Thienamycins | 1989 |
In-vitro interactions of DX-8739, a new carbapenem, meropenem and imipenem with amikacin against multiresistant Pseudomonas aeruginosa.
Topics: Amikacin; Anti-Bacterial Agents; Carbapenems; Drug Interactions; Drug Resistance, Multiple; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Thienamycins | 1996 |
In vitro activity of trovafloxacin in combination with ceftazidime, meropenem, and amikacin.
Topics: Amikacin; Anti-Infective Agents; Bacteria; Ceftazidime; Drug Therapy, Combination; Fluoroquinolones; Humans; Meropenem; Microbial Sensitivity Tests; Naphthyridines; Thienamycins | 1996 |
[In vivo pharmacokinetic of amikacin and its pharmacodynamic in combination with cefepime, cefpirome and meropenem in an in vitro/ex vivo micropig model].
Topics: Amikacin; Animals; Anti-Bacterial Agents; Cefepime; Cefpirome; Cephalosporins; Disease Models, Animal; Drug Therapy, Combination; Female; Humans; In Vitro Techniques; Klebsiella pneumoniae; Meropenem; Perfusion; Serum Bactericidal Test; Swine; Thienamycins | 1997 |
Comparative in vitro interactions of ceftazidime, meropenem, and imipenem with amikacin on multiresistant Pseudomonas aeruginosa.
Topics: Amikacin; Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Drug Interactions; Drug Resistance, Multiple; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Thienamycins | 1997 |
Antibiotic resistance in Pseudomonas aeruginosa: an Italian survey.
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactam Resistance; Ceftazidime; Ciprofloxacin; Drug Resistance, Microbial; Humans; Imipenem; Intensive Care Units; Italy; Meropenem; Microbial Sensitivity Tests; Oxidoreductases; Penicillin Resistance; Pseudomonas aeruginosa; Pyocyanine; Thienamycins | 1998 |
Carbapenemase-producing Pseudomonas aeruginosa in UK.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Ceftazidime; Ciprofloxacin; Drug Resistance, Microbial; Enzyme Inhibitors; Gentamicins; Humans; Imipenem; Meropenem; Metalloproteins; Penicillanic Acid; Penicillins; Piperacillin; Pseudomonas aeruginosa; Tazobactam; Thienamycins; United Kingdom | 1998 |
Postantibiotic effect of some antibiotics on the metabolism of Pseudomonas aeruginosa.
Topics: Adenine; Amikacin; Anti-Bacterial Agents; Carbon Radioisotopes; Cell Division; Ciprofloxacin; Imipenem; Leucine; Meropenem; Nucleic Acid Synthesis Inhibitors; Oxygen Consumption; Pefloxacin; Protein Synthesis Inhibitors; Pseudomonas aeruginosa; Thienamycins | 1998 |
Lowering of plasma valproic acid concentrations during concomitant therapy with meropenem and amikacin.
Topics: Aged; Amikacin; Anti-Bacterial Agents; Anticonvulsants; Drug Antagonism; Female; Humans; Meropenem; Middle Aged; Thienamycins; Valproic Acid | 1998 |
In-vitro effects of a combination of antipseudomonal antibiotics against multi-drug resistant Pseudomonas aeruginosa.
Topics: Amikacin; Anti-Bacterial Agents; Aztreonam; Ceftazidime; Drug Combinations; Drug Resistance, Microbial; Drug Resistance, Multiple; Humans; Meropenem; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 1999 |
[Evaluation of antibiotics by the method of initial bactericidal activity].
Topics: Amikacin; Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Thienamycins | 2000 |
Failure of G-CSF therapy in neutropenia associated with Sjögren's syndrome.
Topics: Amikacin; Anemia; Anti-Bacterial Agents; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Immunocompromised Host; Meropenem; Middle Aged; Neutropenia; Opportunistic Infections; Prednisone; Recombinant Proteins; Sjogren's Syndrome; Thienamycins; Thrombocytopenia; Treatment Failure | 2002 |
[Antimicrobial activity of carbapenems and the combined effect with aminoglycoside against recent clinical isolates of Pseudomonas aeruginosa].
Topics: Amikacin; Anti-Bacterial Agents; Carbapenems; Drug Synergism; Drug Therapy, Combination; Imipenem; Meropenem; Pseudomonas aeruginosa; Thienamycins | 2002 |
[Nocardia cyriacigeorgici: First report of invasive human infection].
Topics: Amikacin; Anti-Bacterial Agents; Brain Abscess; Ceftriaxone; DNA, Ribosomal; Drainage; Humans; Immunocompromised Host; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Nocardia; Nocardia Infections; RNA, Ribosomal, 16S; Sequence Homology, Nucleic Acid; Thienamycins; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination | 2003 |
[Complicating neonatal Escherichia coli meningitis].
Topics: Amikacin; Brain; Drug Therapy, Combination; Echoencephalography; Empyema, Subdural; Escherichia coli Infections; Female; Fosfomycin; Humans; Infant, Newborn; Intensive Care, Neonatal; Magnetic Resonance Imaging; Meningitis, Escherichia coli; Meropenem; Microbial Sensitivity Tests; Patient Care Team; Thienamycins; Treatment Outcome | 2004 |
Intrathecal amikacin for the treatment of pseudomonal meningitis.
Topics: Aged; Amikacin; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Humans; Injections, Intravenous; Injections, Spinal; Meningitis, Bacterial; Meropenem; Pseudomonas aeruginosa; Thienamycins | 2004 |
[Antimicrobial susceptibility of Pseudomonas aeruginosa isolated at Kochi Municipal Central Hospital in the last 3 years].
Topics: Amikacin; Anti-Bacterial Agents; Ceftazidime; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins; Tobramycin | 2004 |
[Antibiotic susceptibility and occurrence of ESBL in Pseudomonas aeruginosa strains isolated from different clinical specimens].
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Cefotaxime; Ceftazidime; Ciprofloxacin; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Tazobactam; Thienamycins; Ticarcillin | 2004 |
In vitro activity of three different antimicrobial agents against ESBL producing Escherichia coli and Klebsiella pneumoniae blood isolates.
Topics: Amikacin; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Blood; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Escherichia coli; Humans; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Thienamycins | 2005 |
Serratia marcescens prosthesis infection successfully treated with meropenem after imipenem failure.
Topics: Aged; Amikacin; Anti-Bacterial Agents; Arthroplasty, Replacement, Knee; Drug Resistance, Bacterial; Female; Humans; Imipenem; Knee Prosthesis; Meropenem; Prosthesis-Related Infections; Serratia Infections; Serratia marcescens; Thienamycins; Treatment Failure; Treatment Outcome | 2005 |
[The combination effects of antibacterial agents against clinical isolated multiple-drug resistant Pseudomonas aeruginosa].
Topics: Amikacin; Anti-Bacterial Agents; Aztreonam; Cefepime; Cefoperazone; Cephalosporins; Ciprofloxacin; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Humans; Meropenem; Microbial Sensitivity Tests; Oxazines; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Sulbactam; Tazobactam; Thienamycins | 2006 |
[Antimicrobial susceptibility of Pseudomonas aeruginosa isolated from urine at one hospital to mainly carbapenem and fluoroquinolone drugs].
Topics: Amikacin; Anti-Infective Agents; Carbapenems; Ceftazidime; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Humans; Imipenem; Meropenem; Oxazines; Piperacillin; Pseudomonas aeruginosa; Thienamycins; Urine | 2006 |
Carbapenem-resistant Acinetobacter baumannii: an emerging threat for patients with post-neurosurgical meningitis.
Topics: Acinetobacter baumannii; Adolescent; Adult; Aged; Amikacin; Anti-Bacterial Agents; Carbapenems; Cefepime; Cefoperazone; Cephalosporins; Ciprofloxacin; Drug Resistance, Bacterial; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Male; Meningitis, Bacterial; Meropenem; Microbial Sensitivity Tests; Middle Aged; Neurosurgical Procedures; Postoperative Complications; Thienamycins; Turkey | 2007 |
[Antibmicrobial susceptibility of Serratia marcescens isolated from hospitalized patients in 2003 - 2005].
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Ciprofloxacin; Cross Infection; Disk Diffusion Antimicrobial Tests; Drug Resistance, Multiple, Bacterial; Gentamicins; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Poland; Serratia marcescens; Thienamycins | 2007 |
Acinetobacter spp. in gunshot injuries.
Topics: Acinetobacter; Acinetobacter Infections; Adult; Amikacin; Anti-Bacterial Agents; Disease Outbreaks; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Humans; Male; Meropenem; Middle Aged; Retrospective Studies; Thienamycins; Timor-Leste; Wounds, Gunshot | 2008 |
Klebsiella pneumoniae brain abscess in two neonates.
Topics: Amikacin; Anti-Bacterial Agents; Brain Abscess; Humans; Infant, Newborn; Infant, Premature; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Thienamycins | 2008 |
[Pseudomonas aeruginosa bacteremia: associations with a source of infection and antibiotic resistance].
Topics: Amikacin; Anti-Bacterial Agents; Bacteremia; Bacteriological Techniques; Ceftazidime; Ciprofloxacin; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Gentamicins; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Retrospective Studies; Thienamycins; Wound Infection | 2009 |
Mortality rate in neonates infected with extended-spectrum beta lactamase-producing Klebsiella species and selective empirical use of meropenem.
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Cohort Studies; Drug Administration Schedule; Female; Humans; Infant, Newborn; Klebsiella; Klebsiella Infections; Male; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pregnancy; Regression Analysis; Retrospective Studies; Risk Factors; Survival Analysis; Thienamycins | 2009 |
Prolonged bacteraemia caused by VIM-1 metallo-beta-lactamase-producing Proteus mirabilis: first report from Italy.
Topics: Aged; Amikacin; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Carbapenems; Cefepime; Cephalosporins; Chromosomes, Bacterial; DNA, Bacterial; Humans; Integrons; Italy; Male; Meropenem; Plasmids; Proteus Infections; Proteus mirabilis; Surgical Wound Infection; Thienamycins; Treatment Failure; Treatment Outcome | 2010 |
Listeria monocytogenes meningitis in two immunocompetent children.
Topics: Amikacin; Ampicillin; Anti-Bacterial Agents; Child; Drug Resistance, Bacterial; Drug Therapy, Combination; Humans; Immunocompetence; Infant; Listeriosis; Male; Meningitis, Listeria; Meropenem; Risk Factors; Spinal Puncture; Thienamycins; Vancomycin | 2009 |
Entry of Burkholderia organisms into respiratory epithelium: CFTR, microfilament and microtubule dependence.
Topics: Actin Cytoskeleton; Amikacin; Anti-Bacterial Agents; Burkholderia gladioli; Burkholderia Infections; Ceftazidime; Cell Line, Transformed; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Therapy, Combination; Epithelial Cells; Humans; Meropenem; Microbial Sensitivity Tests; Microscopy, Electron, Transmission; Microtubules; Respiratory Mucosa; Thienamycins; Virulence | 2010 |
KPC-2 producing Klebsiella pneumoniae and Escherichia coli co-infection in a catheter-related infection.
Topics: Aged, 80 and over; Amikacin; Anti-Bacterial Agents; beta-Lactamases; Catheter-Related Infections; Community-Acquired Infections; Drug Resistance, Multiple, Bacterial; Escherichia coli Infections; Female; Humans; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Pneumonia, Bacterial; Thienamycins | 2011 |
[Investigation of the susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. strains to ertapenem and other carbapenems].
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Ertapenem; Escherichia coli; Escherichia coli Infections; Humans; Imipenem; Klebsiella Infections; Klebsiella oxytoca; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Thienamycins | 2011 |
Successful treatment of Nocardia actinomycetoma with meropenem and amikacin combination therapy.
Topics: Adult; Amikacin; Anti-Bacterial Agents; Drug Therapy, Combination; Humans; Male; Meropenem; Nocardia Infections; Severity of Illness Index; Thienamycins | 2011 |
Effective antibiotics in combination against extreme drug-resistant Pseudomonas aeruginosa with decreased susceptibility to polymyxin B.
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactamases; Drug Resistance, Bacterial; Drug Synergism; Drug Therapy, Combination; Humans; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Ofloxacin; Phylogeny; Polymyxin B; Pseudomonas aeruginosa; Pseudomonas Infections; Rifampin; Thienamycins; Time Factors | 2011 |
Increasing antibiotic activity against a multidrug-resistant Acinetobacter spp by essential oils of Citrus limon and Cinnamomum zeylanicum.
Topics: Acinetobacter; Amikacin; Anti-Bacterial Agents; Cinnamomum zeylanicum; Citrus; Drug Evaluation, Preclinical; Drug Resistance, Multiple, Bacterial; Drug Synergism; Meropenem; Microbial Sensitivity Tests; Oils, Volatile; Thienamycins | 2012 |
Facial ecthyma gangrenosum in 2 preterm neonates.
Topics: Amikacin; Facial Dermatoses; Fatal Outcome; Female; Gangrene; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Meropenem; Necrosis; Neutropenia; Pseudomonas aeruginosa; Pseudomonas Infections; Sepsis; Skin Diseases, Bacterial; Skin Ulcer; Thienamycins | 2012 |
Infective endocarditis due to Enterobacter cloacae resistant to third- and fourth-generation cephalosporins.
Topics: Aged; Amikacin; Anti-Bacterial Agents; beta-Lactam Resistance; Cephalosporins; Endocarditis; Enterobacter cloacae; Enterobacteriaceae Infections; Humans; Male; Meropenem; Thienamycins; Treatment Outcome | 2015 |
Susceptibility of important Gram-negative pathogens to tigecycline and other antibiotics in Latin America between 2004 and 2010.
Topics: Acinetobacter baumannii; Amikacin; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Drug Resistance, Multiple, Bacterial; Enterobacter; Escherichia coli; Imipenem; Klebsiella oxytoca; Klebsiella pneumoniae; Latin America; Meropenem; Microbial Sensitivity Tests; Minocycline; Serratia marcescens; Thienamycins; Tigecycline; United States; United States Food and Drug Administration | 2012 |
bla(IMP) and bla(VIM) mediated carbapenem resistance in Pseudomonas and Acinetobacter species in India.
Topics: Acinetobacter; Acinetobacter Infections; Amikacin; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Disk Diffusion Antimicrobial Tests; Drug Resistance, Bacterial; Genes, Bacterial; Humans; Imipenem; India; Intensive Care Units; Meropenem; Phenotype; Polymerase Chain Reaction; Pseudomonas; Pseudomonas Infections; Thienamycins | 2012 |
Nationwide surveillance of antimicrobial consumption and resistance to Pseudomonas aeruginosa isolates at 203 Japanese hospitals in 2010.
Topics: Amikacin; Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Drug Utilization; Drug Utilization Review; Hospitals; Humans; Imipenem; Incidence; Japan; Meropenem; Microbial Sensitivity Tests; National Health Programs; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Surveys and Questionnaires; Thienamycins | 2013 |
Acinetobacter baumannii infections in a tertiary care hospital in Mexico over the past 13 years.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Amikacin; Anti-Bacterial Agents; DNA, Bacterial; Electrophoresis, Gel, Pulsed-Field; Humans; Imipenem; Intensive Care Units; Meropenem; Mexico; Microbial Sensitivity Tests; Tertiary Healthcare; Thienamycins | 2013 |
[Effects of antibiotics plus efflux pump inhibitors on mutant selection window of Pseudomonas aeruginosa in vitro].
Topics: Amikacin; Antibiotics, Antitubercular; Ciprofloxacin; Dipeptides; Humans; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Thienamycins | 2014 |
The resistome of Pseudomonas aeruginosa in relationship to phenotypic susceptibility.
Topics: Amikacin; Anti-Bacterial Agents; Bacterial Typing Techniques; Base Sequence; beta-Lactamases; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Genome, Bacterial; Humans; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Multilocus Sequence Typing; Pseudomonas aeruginosa; Pseudomonas Infections; Sequence Analysis, DNA; Thienamycins | 2015 |
Even high-dose extended infusions may not yield desired concentrations of β-lactams: the value of therapeutic drug monitoring.
Topics: Adult; Amikacin; Anti-Bacterial Agents; beta-Lactams; Critical Illness; Dose-Response Relationship, Drug; Drug Monitoring; Drug Resistance, Bacterial; Female; Humans; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Sepsis; Thienamycins | 2015 |
Can Plazomicin Alone or in Combination Be a Therapeutic Option against Carbapenem-Resistant Acinetobacter baumannii?
Topics: Acinetobacter baumannii; Acinetobacter Infections; Amikacin; Anti-Bacterial Agents; beta-Lactam Resistance; Cross Infection; Drug Synergism; Drug Therapy, Combination; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Sisomicin; Thienamycins | 2015 |
The Use of Therapeutic Drug Monitoring to Optimize Treatment of Carbapenem-Resistant Enterobacter Osteomyelitis.
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactams; C-Reactive Protein; Drug Monitoring; Drug Resistance, Multiple, Bacterial; Enterobacter cloacae; Enterobacteriaceae Infections; Ertapenem; Female; Fosfomycin; Humans; Meropenem; Middle Aged; Osteomyelitis; Staphylococcal Infections; Staphylococcus epidermidis; Thienamycins | 2015 |
Silver- and fluoride-containing mesoporous bioactive glasses versus commonly used antibiotics: Activity against multidrug-resistant bacterial strains isolated from patients with burns.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Aztreonam; Burns; Carbenicillin; Cefepime; Ceftazidime; Ceftriaxone; Cell Survival; Cephalosporins; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Fluorides; Gentamicins; Glass; Humans; Imipenem; Meropenem; Mice; Microbial Sensitivity Tests; NIH 3T3 Cells; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Silver; Thienamycins; Tobramycin; Wound Infection | 2016 |
Antimicrobial susceptibility of clinical Enterobacteriaceae isolates at the emergency department in a regional hospital: A threat of extended spectrum beta-lactamase-producers among nursing home residents.
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Blood; Drug Resistance, Multiple, Bacterial; Emergency Service, Hospital; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Male; Meropenem; Microbial Sensitivity Tests; Nursing Homes; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Proteus Infections; Proteus mirabilis; Retrospective Studies; Sputum; Taiwan; Thienamycins; Urine | 2016 |
A Microfluidic Channel Method for Rapid Drug-Susceptibility Testing of Pseudomonas aeruginosa.
Topics: Amikacin; Anti-Bacterial Agents; Ceftazidime; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Escherichia coli; Lab-On-A-Chip Devices; Meropenem; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Thienamycins | 2016 |
Neonatal Conjunctivitis Leading to Neonatal Sepsis--A Case Report.
Topics: Amikacin; Anti-Bacterial Agents; Conjunctivitis; Escherichia coli; Escherichia coli Infections; Humans; Infant, Newborn; Male; Meropenem; Sepsis; Thienamycins; Treatment Outcome | 2016 |
Report of an immunocompetent case with disseminated infection due to Nocardia otitidiscaviarum: Identification by 16S rRNA gene sequencing.
Topics: Aged; Amikacin; Anti-Bacterial Agents; Drug Therapy, Combination; Female; Humans; Immunocompetence; Meropenem; Nocardia; Nocardia Infections; RNA, Ribosomal, 16S; Thienamycins; Treatment Outcome | 2016 |
In Vitro Susceptibility of Global Surveillance Isolates of Pseudomonas aeruginosa to Ceftazidime-Avibactam (INFORM 2012 to 2014).
Topics: Africa; Amikacin; Anti-Bacterial Agents; Asia; Azabicyclo Compounds; beta-Lactams; Ceftazidime; Colistin; Drug Combinations; Humans; Latin America; Meropenem; Microbial Sensitivity Tests; Middle East; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2016 |
An Immunocompromised Child with Bloodstream Infection Caused by Two Escherichia coli Strains, One Harboring NDM-5 and the Other Harboring OXA-48-Like Carbapenemase.
Topics: Adolescent; Amikacin; Anti-Bacterial Agents; Aztreonam; Bacterial Proteins; beta-Lactamases; beta-Lactams; Ciprofloxacin; Ertapenem; Escherichia coli; Female; Gentamicins; Humans; Immunocompromised Host; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam; Thienamycins; Tobramycin | 2016 |
In Vitro Activity of Polymyxin B in Combination with Various Antibiotics against Extensively Drug-Resistant Enterobacter cloacae with Decreased Susceptibility to Polymyxin B.
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactamases; Drug Combinations; Drug Dosage Calculations; Drug Resistance, Multiple, Bacterial; Drug Synergism; Enterobacter cloacae; Gene Expression; Humans; Meropenem; Microbial Sensitivity Tests; Minocycline; Models, Statistical; Polymyxin B; Thienamycins; Tigecycline | 2016 |
Pulmonary Nocardiosis: Review of Cases and an Update.
Topics: Adult; Aged; Amikacin; Anti-Bacterial Agents; Cough; Diabetes Mellitus; Dyspnea; Female; Humans; Imipenem; Immunocompromised Host; India; Male; Meropenem; Middle Aged; Nocardia Infections; Pneumonia, Bacterial; Pulmonary Disease, Chronic Obstructive; Thienamycins; Trimethoprim, Sulfamethoxazole Drug Combination; Tuberculosis, Pulmonary | 2016 |
Empirical monotherapy with meropenem or combination therapy: the microbiological point of view.
Topics: Amikacin; Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Bacterial; Drug Therapy, Combination; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Meropenem; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Spain; Thienamycins | 2016 |
Correlation between antimicrobial consumption and antimicrobial resistance of Pseudomonas aeruginosa in a hospital setting: a 10-year study.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; beta-Lactams; Carbapenems; Drug Resistance, Bacterial; Drug Utilization; Gentamicins; Hospitals; Humans; Imipenem; Meropenem; Pseudomonas aeruginosa; Serbia; Thienamycins | 2016 |
Multidrug-Resistant Pathogens in Hospitalized Syrian Children.
Topics: Adolescent; Amikacin; Anti-Bacterial Agents; Armed Conflicts; Bacterial Infections; Child; Child, Preschool; Colistin; Critical Illness; Drug Resistance, Multiple, Bacterial; Female; Gram-Negative Bacteria; Gram-Positive Bacteria; Hospitalization; Humans; Infant; Infant, Newborn; Israel; Male; Meropenem; Multiple Trauma; Syria; Thienamycins | 2017 |
Tigecycline Therapy in an Infant for Ventriculoperitoneal Shunt Meningitis.
Topics: Amikacin; Drug Therapy, Combination; Humans; Hydrocephalus; Infant; Infant, Premature, Diseases; Infusions, Intravenous; Injections, Spinal; Klebsiella Infections; Klebsiella pneumoniae; Male; Meningitis, Bacterial; Meropenem; Microbial Sensitivity Tests; Minocycline; Off-Label Use; Salvage Therapy; Thienamycins; Tigecycline; Ventriculoperitoneal Shunt | 2017 |
In vitro activity of ceftolozane/tazobactam in combination with other classes of antibacterial agents.
Topics: Amikacin; Aztreonam; Cephalosporins; Drug Antagonism; Drug Synergism; Drug Therapy, Combination; Gram-Negative Bacteria; Humans; Meropenem; Microbial Sensitivity Tests; Tazobactam; Tigecycline | 2017 |
IMP-6 Carbapenemase-Producing Enterobacteriaceae Bacteremia Successfully Treated with Amikacin-Meropenem in Two Patients.
Topics: Aged; Amikacin; Anti-Bacterial Agents; Bacteremia; Bacterial Proteins; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Drug Therapy, Combination; Enterobacteriaceae Infections; Humans; Male; Meropenem; Microbial Sensitivity Tests; Thienamycins; Treatment Outcome | 2017 |
Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study.
Topics: Adolescent; Amikacin; Aminoglycosides; Anti-Bacterial Agents; Bacteremia; Carbapenems; Cephalosporins; Child; Child, Preschool; Drug Resistance, Multiple, Bacterial; Female; Fever; Fluoroquinolones; Humans; Male; Meropenem; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Thienamycins | 2017 |
Antibiotics susceptibility patterns of uropathogenic E. coli with special reference to fluoroquinolones in different age and gender groups.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Cefoperazone; Child; Child, Preschool; Cross-Sectional Studies; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Fluoroquinolones; Humans; Imipenem; Infant; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Sulbactam; Tazobactam; Urinary Tract Infections; Young Adult | 2017 |
Biological evaluation of diphenyleneiodonium chloride (DPIC) as a potential drug candidate for treatment of non-tuberculous mycobacterial infections.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Bacterial Load; Chlorocebus aethiops; Disease Models, Animal; Drug Discovery; Kinetics; Meropenem; Mice; Microbial Sensitivity Tests; Mycobacterium Infections, Nontuberculous; Neutropenia; Nontuberculous Mycobacteria; Onium Compounds; Small Molecule Libraries; Thienamycins; Vero Cells | 2017 |
Trend of Antibiotic Sensitivity of Escherichia Coli in Patients with Urinary Tract Infection.
Topics: Adolescent; Adult; Amikacin; Anti-Bacterial Agents; Drug Resistance, Microbial; Escherichia coli; Escherichia coli Infections; Female; Humans; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Nitrofurantoin; Urinary Tract Infections; Young Adult | 2017 |
[Skin pigmentation induced by meropenem and levofloxacin].
Topics: Aged; Amikacin; Anti-Bacterial Agents; Drug Therapy, Combination; Humans; Hyperpigmentation; Levofloxacin; Male; Meropenem; Metatarsus; Osteitis; Rifampin | 2017 |
Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2013-2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazoba
Topics: Amikacin; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Hospitals; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thienamycins | 2018 |
Antimicrobial activity of plazomicin against Enterobacteriaceae-producing carbapenemases from 50 Brazilian medical centers.
Topics: Amikacin; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Brazil; Carbapenem-Resistant Enterobacteriaceae; Colistin; Drug Resistance, Multiple, Bacterial; Gentamicins; Hospitals; Humans; Meropenem; Microbial Sensitivity Tests; Sisomicin; Thienamycins | 2018 |
Establishment and Validation of Galleria mellonella as a Novel Model Organism To Study Mycobacterium abscessus Infection, Pathogenesis, and Treatment.
Topics: Amikacin; Animals; Larva; Levofloxacin; Linezolid; Meropenem; Moths; Mycobacterium abscessus; Mycobacterium Infections, Nontuberculous; Tigecycline | 2018 |
Comparative transcriptomics of multidrug-resistant Acinetobacter baumannii in response to antibiotic treatments.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Amikacin; Anti-Bacterial Agents; DNA Transposable Elements; Drug Resistance, Multiple, Bacterial; Gene Expression Regulation, Bacterial; Gene Ontology; High-Throughput Nucleotide Sequencing; Humans; Imipenem; Meropenem; Molecular Sequence Annotation; Transcriptome | 2018 |
Antibiotic resistance evolution of Pseudomonas aeruginosa in cystic fibrosis patients (2010-2013).
Topics: Adolescent; Adult; Amikacin; Anti-Bacterial Agents; Ceftazidime; Child; Ciprofloxacin; Cystic Fibrosis; Drug Resistance, Microbial; Female; Humans; Levofloxacin; Longitudinal Studies; Male; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Young Adult | 2018 |
Potential pathogenicity of Inquilinus limosus in a pediatric patient with cystic fibrosis.
Topics: Amikacin; Anti-Bacterial Agents; Child; Ciprofloxacin; Clindamycin; Cystic Fibrosis; Gram-Negative Bacterial Infections; Humans; Male; Meropenem; Methicillin-Resistant Staphylococcus aureus; Rhodospirillaceae; Stenotrophomonas maltophilia; Virulence | 2018 |
The tigecycline evaluation and surveillance trial; assessment of the activity of tigecycline and other selected antibiotics against gram-positive and gram-negative pathogens from France collected between 2004 and 2016.
Topics: Acinetobacter baumannii; Amikacin; Drug Resistance, Multiple, Bacterial; Enterococcus; Escherichia coli; France; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Klebsiella pneumoniae; Levofloxacin; Linezolid; Meropenem; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Streptococcus pneumoniae; Tigecycline; Vancomycin | 2018 |
Ceftazidime/avibactam versus standard-of-care agents against carbapenem-resistant Enterobacteriaceae harbouring blaKPC in a one-compartment pharmacokinetic/pharmacodynamic model.
Topics: Amikacin; Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Ceftazidime; Drug Combinations; Enterobacteriaceae Infections; Meropenem; Models, Theoretical; Polymyxin B; Treatment Outcome | 2018 |
Antibacterial effect of ceftolozane/tazobactam in combination with amikacin against aerobic Gram-negative bacilli studied in an in vitro pharmacokinetic model of infection.
Topics: Amikacin; Anti-Bacterial Agents; Bacterial Load; beta-Lactamase Inhibitors; Cephalosporins; Drug Therapy, Combination; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Meropenem; Microbial Sensitivity Tests; Microbial Viability; Models, Theoretical; Tazobactam | 2018 |
Effect of increasing meropenem MIC on the killing activity of meropenem in combination with amikacin or polymyxin B against MBL- and KPC-producing Enterobacter cloacae.
Topics: Amikacin; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Cytoskeletal Proteins; Drug Synergism; Enterobacter cloacae; Enterobacteriaceae Infections; Humans; Meropenem; Microbial Sensitivity Tests; Microbial Viability; Multilocus Sequence Typing; Polymyxin B | 2018 |
AmpC beta-lactamases in Klebsiella pneumoniae: An emerging threat to the paediatric patients.
Topics: Adolescent; Amikacin; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Cefoperazone; Cefoxitin; Cephalosporins; Child; Child, Preschool; Ciprofloxacin; Cross-Sectional Studies; Disk Diffusion Antimicrobial Tests; Drug Combinations; Drug Resistance, Bacterial; Female; Hospitals, Pediatric; Humans; Imipenem; Infant; Infant, Newborn; Klebsiella Infections; Klebsiella pneumoniae; Levofloxacin; Male; Meropenem; Microbial Sensitivity Tests; Pakistan; Piperacillin, Tazobactam Drug Combination; Sulbactam | 2018 |
Killing activity of meropenem in combination with amikacin against VIM- or KPC-producing Enterobacteriaceae that are susceptible, intermediate, or resistant to amikacin.
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactamases; Drug Synergism; Enterobacteriaceae; Meropenem; Microbial Viability | 2019 |
Nebulized Amikacin and Fosfomycin for Severe Pseudomonas aeruginosa Pneumonia: An Experimental Study.
Topics: Administration, Inhalation; Administration, Intravenous; Amikacin; Animals; Anti-Bacterial Agents; Bacterial Load; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Fosfomycin; Lung; Meropenem; Nebulizers and Vaporizers; Pneumonia; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Random Allocation; Swine; Trachea | 2019 |
Antimicrobial activity of novel chalcones and modulation of virulence factors in hospital strains of Acinetobacter baumannii and Pseudomonas aeruginosa.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Biofilms; Chalcones; Ciprofloxacin; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Synergism; Hospitals; Humans; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Pyocyanine; Virulence Factors | 2019 |
Towards tailored regimens in the treatment of drug-resistant tuberculosis: a retrospective study in two Italian reference Centres.
Topics: Adult; Amikacin; Antitubercular Agents; Drug Resistance, Bacterial; Extensively Drug-Resistant Tuberculosis; Female; Humans; Italy; Laboratories, Hospital; Linezolid; Male; Meropenem; Retrospective Studies; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2019 |
Nocardial endocarditis in native aortic valve with nocardial sepsis in a case of breast cancer.
Topics: Amikacin; Anti-Bacterial Agents; Anticoagulants; Aortic Valve; Breast Neoplasms; Central Venous Catheters; Clopidogrel; Cough; Endocarditis, Bacterial; Fatigue; Female; Headache; Heart Valve Prosthesis Implantation; Humans; Meropenem; Middle Aged; Nocardia; Nocardia Infections; Platelet Aggregation Inhibitors; Radiography, Thoracic; Sepsis; Treatment Outcome; Warfarin | 2019 |
[Septic shock secondary to Elizabethkingia meningoseptica: A case report].
Topics: Aged; Amikacin; Anti-Bacterial Agents; Chryseobacterium; Drug Therapy, Combination; Flavobacteriaceae Infections; Humans; Male; Meropenem; Rifampin; Shock, Septic; Tigecycline; Trimethoprim, Sulfamethoxazole Drug Combination | 2019 |
The treatment of nosocomial meningitis and brain abscess by carbapenem-resistant
Topics: Adult; Amikacin; Anti-Bacterial Agents; Brain Abscess; Carbapenem-Resistant Enterobacteriaceae; Cross Infection; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Meningitis; Meropenem; Microbial Sensitivity Tests; Pneumonia; Sulfamethoxazole | 2023 |
An
Topics: Amikacin; Anti-Bacterial Agents; Biofilms; Ciprofloxacin; Drug Synergism; Escherichia coli; Fosfomycin; Humans; Meropenem; Microbial Sensitivity Tests; Urinary Tract Infections | 2019 |
Synergetic Effects of Combined Treatment of Colistin With Meropenem or Amikacin on Carbapenem-Resistant
Topics: Amikacin; Anti-Bacterial Agents; Carbapenem-Resistant Enterobacteriaceae; Colistin; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, Combination; Enterobacteriaceae Infections; Humans; Meropenem; Microbial Sensitivity Tests; Multilocus Sequence Typing | 2019 |
Isothermal microcalorimetry minimal inhibitory concentration testing in extensively drug resistant Gram-negative bacilli: a multicentre study.
Topics: Acinetobacter baumannii; Amikacin; Anti-Bacterial Agents; Calorimetry; Ciprofloxacin; Colistin; Drug Resistance, Multiple, Bacterial; Escherichia coli; Humans; Italy; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Netherlands; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Spain; Sweden | 2020 |
Comparison of two different anti-infectious approaches after high-dose chemotherapy and autologous stem cell transplantation for hematologic malignancies in a 12-year period in British Hospital, Uruguay.
Topics: Adolescent; Adult; Aged; Amikacin; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Ceftazidime; Ciprofloxacin; Febrile Neutropenia; Female; Fever of Unknown Origin; Hematologic Neoplasms; Humans; Incidence; Levofloxacin; Male; Meropenem; Middle Aged; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Transplantation, Autologous; Uruguay; Young Adult | 2020 |
Activity of Cefiderocol and Comparators against Isolates from Cancer Patients.
Topics: Acinetobacter; Amikacin; Anti-Bacterial Agents; Azabicyclo Compounds; Carbapenem-Resistant Enterobacteriaceae; Cefiderocol; Ceftazidime; Cephalosporins; Drug Combinations; Gram-Negative Bacteria; Humans; Meropenem; Microbial Sensitivity Tests; Neoplasms; Pseudomonas aeruginosa; Stenotrophomonas maltophilia | 2020 |
Pseudomonas Aeruginosa as the Main Causative Agent of Osteomyelitis and its Susceptibility to Antibiotics.
Topics: Amikacin; Anti-Bacterial Agents; Chronic Disease; Doripenem; Gentamicins; Humans; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Osteomyelitis; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies | 2020 |
In vitro activity of polymyxin B in combination with meropenem, amikacin and gentamicin against Klebsiella pneumoniae clinical isolates co-harbouring aminoglycoside-modifying enzymes, bla
Topics: Amikacin; Aminoglycosides; beta-Lactamases; Gentamicins; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Polymyxin B | 2020 |
Prevalence of O25b-ST131 clone and fosfomycin resistance in urinary Escherichia coli isolates and their relation to CTX-M determinant.
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactamases; Ceftriaxone; Cefuroxime; Ciprofloxacin; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Fosfomycin; Humans; Meropenem; Microbial Sensitivity Tests; Polymerase Chain Reaction; Prevalence; Urinary Tract Infections; Virulence Factors | 2020 |
Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam and Comparators Tested Against
Topics: Amikacin; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactam Resistance; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Phenotype; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Tazobactam; United States; Whole Genome Sequencing | 2021 |
Efficacy of meropenem and amikacin combination therapy against carbapenemase-producing Klebsiella pneumoniae mouse model of pneumonia.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Pneumonia | 2020 |
Ultrastructural changes caused by the combination of intravenous immunoglobulin with meropenem, amikacin and colistin in multidrug-resistant Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Amikacin; Anti-Bacterial Agents; Colistin; Drug Resistance, Multiple, Bacterial; Drug Synergism; Humans; Immunoglobulins, Intravenous; Meropenem; Microbial Sensitivity Tests | 2020 |
Thermal Stability and in Vitro Elution Kinetics of Alternative Antibiotics in Polymethylmethacrylate (PMMA) Bone Cement.
Topics: Acinetobacter baumannii; Amikacin; Anti-Bacterial Agents; Bone Cements; Drug Stability; Fosfomycin; Kinetics; Meropenem; Microbial Sensitivity Tests; Polymethyl Methacrylate; Prosthesis-Related Infections; Staphylococcus aureus; Tobramycin | 2021 |
In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016-2018).
Topics: Amikacin; Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamases; Ceftazidime; Citrobacter koseri; Colistin; Drug Combinations; Enterobacteriaceae; Epidemiological Monitoring; Escherichia coli; Humans; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Tigecycline | 2021 |
Identifying alternative antibiotics that elute from calcium sulfate beads for treatment of orthopedic infections.
Topics: Amikacin; Anti-Bacterial Agents; Calcium Sulfate; Cefazolin; Meropenem; Minocycline; Tobramycin; Vancomycin | 2022 |
Carbapenem-resistant K. pneumoniae exhibiting clinically undetected amikacin and meropenem heteroresistance leads to treatment failure in a murine model of infection.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Carbapenems; Disease Models, Animal; Klebsiella pneumoniae; Meropenem; Mice; Microbial Sensitivity Tests; Treatment Failure | 2021 |
Antimicrobial resistance profiles and associated factors of Acinetobacter and Pseudomonas aeruginosa nosocomial infection among patients admitted at Dessie comprehensive specialized Hospital, North-East Ethiopia. A cross-sectional study.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Adolescent; Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Child; Child, Preschool; Cross Infection; Cross-Sectional Studies; Drug Resistance, Multiple, Bacterial; Ethiopia; Female; Hospitals, Special; Humans; Infant; Infant, Newborn; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Patient Admission; Pseudomonas aeruginosa; Pseudomonas Infections; Risk Factors; Treatment Outcome; Young Adult | 2021 |
Variants of Tn
Topics: Acinetobacter baumannii; Acinetobacter Infections; Amikacin; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Genome, Bacterial; Macrolides; Meropenem; Phylogeny; Sequence Alignment | 2022 |
Introducing the Escalation Antibiogram: A Simple Tool to Inform Changes in Empiric Antimicrobials in the Nonresponding Patient.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Bacteremia; Ceftriaxone; Ciprofloxacin; Ertapenem; Gentamicins; Gram-Negative Bacteria; Humans; Meropenem; Microbial Sensitivity Tests; Piperacillin, Tazobactam Drug Combination; Tobramycin; Trimethoprim, Sulfamethoxazole Drug Combination | 2022 |
Antimicrobial susceptibility testing of clinical isolates of Gram-negative bacilli collected in Morocco by the ATLAS Global Surveillance Program from 2018 to 2020.
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Gram-Negative Bacteria; Meropenem; Morocco; Pseudomonas aeruginosa | 2022 |
Antimicrobial resistance, virulence factors, and genotypes of Pseudomonas aeruginosa clinical isolates from Gorgan, northern Iran.
Topics: Amikacin; Anti-Bacterial Agents; Ceftazidime; Ciprofloxacin; Colistin; Deoxyribonucleases; Drug Resistance, Bacterial; Genotype; Gentamicins; Humans; Imipenem; Iran; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Pancreatic Elastase; Phospholipases; Piperacillin; Piperacillin, Tazobactam Drug Combination; Polymyxin B; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Virulence Factors | 2022 |
In Vitro Activity of Plazomicin Against Carbapenem Resistant Klebsiella pneumoniae Strains.
Topics: Amikacin; Aminoglycosides; Anti-Bacterial Agents; Carbapenem-Resistant Enterobacteriaceae; Gentamicins; Humans; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Sisomicin; Tobramycin | 2022 |
Efficacy of Amikacin and Meropenem on Colistin-Induced
Topics: Amikacin; Anti-Bacterial Agents; Colistin; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests | 2022 |
The evaluation of antibiotic susceptibility pattern and associated risk factors of UTI in tertiary care hospital of Peshawar.
Topics: Amikacin; Anti-Bacterial Agents; Escherichia coli; Female; Fosfomycin; Humans; Imipenem; Klebsiella pneumoniae; Linezolid; Male; Meropenem; Pseudomonas aeruginosa; Risk Factors; Tertiary Care Centers; Urinary Tract Infections; Vancomycin | 2022 |
Antibiotic allergy in children with cystic fibrosis: A retrospective case-control study.
Topics: Amikacin; Anti-Bacterial Agents; Azithromycin; Case-Control Studies; Ceftazidime; Child; Ciprofloxacin; Cystic Fibrosis; Drug Hypersensitivity; Humans; Levofloxacin; Meropenem; Piperacillin; Retrospective Studies; Tazobactam; Trimethoprim, Sulfamethoxazole Drug Combination | 2022 |
Global update on the in vitro activity of tigecycline and comparators against isolates of Acinetobacter baumannii and rates of resistant phenotypes (2016-2018).
Topics: Acinetobacter baumannii; Amikacin; Anti-Bacterial Agents; Colistin; Gram-Negative Bacteria; Levofloxacin; Meropenem; Phenotype; Tigecycline | 2022 |
Isothermal microcalorimetry vs checkerboard assay to evaluate in-vitro synergism of meropenem-amikacin and meropenem-colistin combinations against multi-drug-resistant Gram-negative pathogens.
Topics: Amikacin; Anti-Bacterial Agents; Colistin; Drug Resistance, Multiple, Bacterial; Drug Synergism; Escherichia coli; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests | 2022 |
Aetiology, antimicrobial susceptibility and outcome of children with sepsis, admitted at Muhimbili National Hospital, Dar es Salaam.
Topics: Amikacin; Amoxicillin-Potassium Clavulanate Combination; Ampicillin; Anti-Bacterial Agents; Anti-Infective Agents; Ceftriaxone; Child, Preschool; Ciprofloxacin; Clindamycin; Coagulase; Cross-Sectional Studies; Escherichia coli; Female; Gentamicins; Gram-Negative Bacteria; Gram-Positive Bacteria; Hospitals; Humans; Infant; Male; Meropenem; Microbial Sensitivity Tests; Prospective Studies; Sepsis; Staphylococcus aureus; Tanzania | 2022 |
Analysis of drug resistance genes of integrons in clinical isolates of Escherichia coli from elderly bloodstream infections.
Topics: Aged; Amikacin; Anti-Bacterial Agents; beta-Lactamases; Cefepime; Cefoxitin; Clavulanic Acid; Drug Resistance; Escherichia coli; Escherichia coli Infections; Gentamicins; Humans; Integrons; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Minocycline; Sepsis; Ticarcillin; Trimethoprim, Sulfamethoxazole Drug Combination | 2022 |
Whole genome sequencing of OXA-232-producing
Topics: Amikacin; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Chromosomes; Ciprofloxacin; DNA Transposable Elements; Ertapenem; Humans; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Multilocus Sequence Typing; Phylogeny; Plasmids; Sepsis; Virulence; Virulence Factors; Whole Genome Sequencing | 2022 |
Genotypic resistance determined by whole genome sequencing versus phenotypic resistance in 234 Escherichia coli isolates.
Topics: Amikacin; Amoxicillin; Anti-Bacterial Agents; Cefepime; Cefotaxime; Ceftazidime; Ciprofloxacin; Clavulanic Acid; Escherichia coli; Escherichia coli Infections; Genotype; Gentamicins; Humans; Meropenem; Microbial Sensitivity Tests; Phenotype; Piperacillin; Retrospective Studies; Tazobactam; Tobramycin; Whole Genome Sequencing | 2023 |
A 12-Year Retrospective Analysis of Blood Culture Isolates in the Intensive Care Unit of a Tertiary Hospital in China.
Topics: Amikacin; Anti-Bacterial Agents; Blood Culture; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Imipenem; Intensive Care Units; Linezolid; Meropenem; Microbial Sensitivity Tests; Retrospective Studies; Sepsis; Teicoplanin; Tertiary Care Centers; Vancomycin | 2023 |
Distribution of microbes and antimicrobial susceptibility in patients with diabetic foot infections in South China.
Topics: Amikacin; Anti-Bacterial Agents; Coinfection; Diabetes Mellitus; Diabetic Foot; Ertapenem; Gram-Negative Bacteria; Humans; Meropenem; Retrospective Studies; Tigecycline | 2023 |
Inhaled amikacin for pneumonia treatment and dissemination prevention: an experimental model of severe monolateral Pseudomonas aeruginosa pneumonia.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Meropenem; Microbial Sensitivity Tests; Models, Theoretical; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Swine | 2023 |
Incidence of ESBLs and carbapenemases among Enterobacterales and carbapenemases in Pseudomonas aeruginosa isolates collected globally: results from ATLAS 2017-2019.
Topics: Amikacin; Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; beta-Lactamases; Ceftazidime; Ciprofloxacin; Drug Combinations; Escherichia coli; Incidence; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa | 2023 |
In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in the Asia-Pacific region: SMART 2017-2020.
Topics: Amikacin; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Tazobactam; Thailand | 2023 |
Propranolol restores susceptibility of XDR Gram-negative pathogens to meropenem and Meropenem combination has been evaluated with either tigecycline or amikacin.
Topics: Amikacin; Carbapenems; Escherichia coli; Humans; Meropenem; Propranolol; Tigecycline | 2023 |
Antibiotic Guidelines for Critically Ill Patients in Nigeria.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Ceftriaxone; Clavulanic Acid; Community-Acquired Infections; Critical Illness; Cross Infection; Fluconazole; Humans; Meropenem; Microbial Sensitivity Tests; Nigeria; Piperacillin, Tazobactam Drug Combination; Pneumonia; Prospective Studies; Urinary Tract Infections | 2023 |
In Vitro antibiotic combinations of Colistin, Meropenem, Amikacin, and Amoxicillin/clavulanate against multidrug-resistant Klebsiella pneumonia isolated from patients with ventilator-associated pneumonia.
Topics: Amikacin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Colistin; Drug Synergism; Humans; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Pneumonia, Ventilator-Associated | 2023 |
In vitro evaluation of human intravenous immunoglobulin in combination with antimicrobials and human serum against multidrug-resistant isolates of Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Colistin; Drug Resistance, Multiple, Bacterial; Drug Synergism; Humans; Immunoglobulins, Intravenous; Meropenem; Microbial Sensitivity Tests | 2023 |